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THERAPY FOR CANINE BLADDER CANCER 
 
 Urinary bladder cancer is the most common cancer of the canine urinary 
tract, with transitional cell carcinoma (TCC) being the most commonly diagnosed 
tumor type.  TCC is aggressive, invasive and fatal for most dogs.  If left 
untreated, TCC of the canine bladder has average survival times less than one 
year. 
 Optimal treatment of this malignancy remains a topic of debate.  Different 
treatment options exist, but many complicating factors make the probability of 
cure very low, regardless of treatment type, and most care is palliative in nature. 
Radiation therapy is a possible treatment option, however dailyshape, 
size, and positional changes (motion) of the bladder and surrounding soft tissue 
structures often make this modality difficult to incorporate into a curative-intent 
treatment plan.  This study was designed to investigate and quantify the motion 
characteristics experienced by the canine urinary bladder from day to day.  
Additionally, this information was then used to examine possible treatment 





bladder cancer patients. Retrospective cone beam CT (CBCT) image data 
from ten dogs were used in this study.  Organs of interest were contoured on 
each daily treatment CBCT data set and the images, along with the contours, 
were registered (fused) to the original (reference) planning CT.  Quantification of 
bladder motion was determined by making measurements relative to the 
planning CT.  Dosimetric data for the organs of interest were determined using 
dose volume histograms generated from sample treatment plans.  
 Results indicate a wide range in bladder motion throughout treatment, 
which partly depends on the methods used for patient positioning (set-up).  Of 
the three patient positioning methods evaluated (dorsal, sternal, and lateral 
recumbency), the least amount of bladder variability, as well as lowest rectal 
dose, is seen when dogs are placed in lateral recumbency.  Using these motion 
characteristics, we were able to develop different treatment planning and set-up 
scenarios that allow for a curative dose to be delivered to the bladder, while 
simultaneously reducing the dose delivered to the nearby sensitive rectal tissue.  
All advanced treatment planning techniques produce a better dose distribution 
than traditional parallel opposed planning, with adaptive radiation therapy (ART) 
planning techniques showing the most advantageous dose distribution.  
These results allow for a more informed approach to the treatment of 
canine bladder cancer, as well as providing possible curative-intent treatment 
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 Over the past few decades, the use of external beam radiation therapy 
(RT) as a cancer treatment modality for companion animals has increased1-3.  
The technology involved in the RT process has evolved for both planning and 
delivery, and the number of facilities that are able to offer RT as a treatment 
option continues to increase1, 4, with the Veterinary Cancer Society listing 69 
clinics in 2010 that offer radiation therapy4, up from 42 identified in 20011.  
Technological advances in diagnosis, planning and treatment delivery have 
enabled RT to become an effective treatment option for most tumors, especially 
when combined with surgery5.  Unfortunately, due to many contributing factors, 
this same success is not seen with all types of tumors.  For instance bladder 
cancer, as evidenced by low survival rates when treated solely with RT6, is still 
seen by many to be most effectively treated by cystectomy of the lesion, followed 
by chemotherapy.  RT is oftentimes considered a reasonable palliative option7 
but geometric uncertainties in organ motion require increases in treatment 
margins which can increase the risk for normal tissue complications8.  Thus, the 
use of RT for curative-intent treatment is often difficult.  Such low survival rates 
and uncertainties in organ motion indicate that there is an opportunity for 





curative-intent treatment option for urinary bladder cancer8. To make RT a 
curative, bladder-sparing alternative to cystectomy, some commonly encountered 
obstacles must be overcome.  The goal of treatment planning is to increase the 
dose to the tumor while simultaneously limiting the dose to the surrounding 
tissues9.  This introduces the possibility of acute and late effects on normal 
tissues surrounding the bladder 3, 6, 10-14.  In order to address these issues, the 
daily motion variations experienced by the canine bladder and surrounding 
tissues need to be understood5.  Currently, there is little bladder motion data 
available and the majority is from human studies, many of these being gathered 
from prostate studies8, 15 -25.  Using cone beam computed tomography (CBCT) 
imaging technology at Colorado State University Veterinary Teaching Hospital 
(CSUVTH) the geometric variations of the bladder were quantified and 
subsequently employed to develop RT protocols for the treatment of canine 
bladder cancer. 
 
1.2 Canine Transitional Cell Carcinoma 
 1.2a TCC Incidence 
 Urinary bladder cancer is the most common neoplasm of the canine 
urinary tract, with the most frequently diagnosed type being transitional cell 
carcinoma (TCC)26.  While the true incidence is not known, it is thought that 
between 20,000 to 30,000 dogs are affected by TCC each year in the United 





decades28.  TCC is more common in certain breeds, including Scottish Terriers28 
(Table 1.1). 
 
 1.2b TCC Pathology 
 TCC is an invasive, progressive and ultimately fatal cancer that results in 
death due to post-renal obstruction within 3-12 months of diagnosis29 if treatment 
is not administered.  Most canine TCC tumor samples are intermediate to high 
grade, poorly differentiated and are of an infiltrative nature26, 28.  At the time of 















Table 1.1  Breed and Risk of Developing Bladder Can cer 28 
Breed  Risk Factor  
Scottish Terrier 18.09 
Shetland Sheepdog 4.46 
Beagle 4.15 
Wire Hair Fox Terrier 3.2 
West Highland White Terrier 3.02 
Labrador Retriever 0.46 
Golden Retriever 0.46 
 













 1.2c TCC Causes 
 The etiology of bladder TCC is not known, but is most likely due to 
multiple factors28.  It is suspected that a combination of genetic and 
environmental causes, such as exposure to insecticides, obesity, sex and breed, 
contribute to the development of this malignancy27-30.  It has been demonstrated 
that cigarette smoke, occupational chemical exposure and insecticides are 
powerful causal agents in the development of human bladder cancer30, and this 
holds true for canine patients as well.  Exposure to insecticides and herbicides 
has been shown to increase the risk of a dog developing TCC of the urinary 
bladder28-30.  A study of 58 cases showed that dogs exposed to insecticides had 
double the risk of control dogs of developing bladder TCC30.  Many of these 
products are often petroleum-based, which have been identified as a risk factor 
for human bladder cancer30.  
 In the above study, obese dogs had a higher incidence of bladder TCC 
than did the control dogs30, and this was attributed to the lipophilic nature of 
many chemicals which become stored in the dog’s adipose tissue28, 30.   
 Studies have also shown the increased incidence of bladder cancer in 
female dogs.  In a series of 102 dogs, female dogs were treated for bladder TCC 
1.7 times as often as male dogs28.  Higher incidence in female dogs has been 
attributed to the higher percentage of body fat in female dogs versus male dogs, 
which acts to sequester the lipophilic chemicals in the insecticides28, 30.  Female 
dogs urinate less frequently than male dogs which would result in less 





genetic28 and may be attributed to different pathways that activate or detoxify 
different carcinogens, such as benzene, which is a common ingredient in many 
insecticides28, 29. 
 
 1.2d TCC Diagnosis 
 Clinical signs of TCC include incontinence, difficulty urinating, pollakiuria, 
and hematuria.  Signs of renal failure (vomiting, anorexia, dehydration) may 
occur, as well as urethral or ureteral obstruction29, in advanced cases.  Diagnosis 
begins with either cytologic diagnosis from urine sediment cytology or intentional 
urinary tract catheterization, or histopathologic examination of a tissue sample or 
biopsy through cystotomy, cystoscopy or catheter biopsy31.  Staging is then 
performed through physical examination, radiologic imaging of the thorax, 
bladder ultrasound, and abdominal radiography, ultrasound, and/or CT to further 
asses the location of the tumor and disease extent. 
 Approximately 37% of dogs show metastatic disease at the time of 
diagnosis26, 28 and metastatic disease is reported in approximately 50% of cases 
at time of death 26, 29, 32.  Sites of bladder TCC metastases in a postmortem 
examination of 50 dogs included lung (28%), regional lymph nodes (26%), liver 
(18%), kidney (4%), spleen (4%), prescapular lymph nodes (4%) and uterus (4%) 
one case each (2%) of metastases in mesenteric lymph nodes, cecum, bronchial 
lymph nodes, vertebrae, ilium, colon, abdominal wall, diaphragm, renal lymph 
node, and oral mucosa28.  Death due to urinary tract obstruction often occurs 





controlled.  Death due to metastatic disease occurs more often if the primary 
tumor can be controlled28. 
 
1.3  Treatment Options 
 Treatment options depend on the location and invasiveness of the tumor 
and include surgery, chemotherapy, and radiation therapy, or some combination 
of these modalities12.  Unfortunately, a unique combination of factors, as well as 
a low probability of cure, makes TCC difficult to effectively treat and most cases 
are treated with palliative, rather than curative, intent32 (Table 1.2).  Prognosis is 
often worse with a younger age of onset, more invasive tumors, and tumors that 
also involve the prostate gland. 
 
 1.3a Surgical Excision 
 Surgical excision without adjuvant therapy is not considered curative.  
Furthermore, surgical excision is not often considered a treatment option due to 
the frequent location of tumors in the trigone area or urethra28,33, the possibility 
that there are multifocal lesions that differ in aggressiveness34, and the concern 
of tumor seeding32, 35-37.  Local disease is often advanced and involves the 
muscular layers of the bladder and urethra26,34.  Invasive tumors involving the 
muscular layers of the bladder also require more radical surgeries, to which 
owners may not agree due to the possibility of side effects, such as urinary 
incontinence and increased urinary frequency28.   Partial cystectomy has been 





Recurrence is also thought to occur in up to 70% of human cases of bladder 
TCC38.  Median survival times for canine patients have been reported at just over 
100 days when surgical debulking, with or without partial cystectomy, is the only 
treatment26. 
 Another concern that prevents surgical excision from being an effective 
single-agent  effective treatment option is the thought that the entire bladder 
mucosa has likely been exposed to the inciting carcinogen as it is metabolized 
and exits the urinary tract in the urine7.  New lesions occurring after surgery are 
often noticed at sites distant from the surgical site28. 
 
 1.3b Medical Therapy 
 Chemotherapeutic agents are often used to treat canine bladder TCC due 
to the aggressive nature of the disease and the high metastatic rate32, however 
an effective protocol has not been established.  Platinum-based drugs (cisplatin, 
carboplatin, etc.) and non-steroidal anti-inflammatory drugs (NSAID) (cox 
inhibitors, piroxicam) have been used with only moderate success32.  While 
single agent chemotherapy has been shown to help prolong or improve the 
quality of the dog’s life, it is not curative in most cases and the toxicity associated 
with more aggressive therapies are often not tolerated by owners32.   
 Piroxicam has been shown to provide both anti-cancer and analgesic 
benefits, however it carries with it the possibility of gastrointestinal toxicity29, 39, 40.  
Piroxicam has been used with some success and has been reported to produce 





treatment show median survival times of only about six months.  More recently, 
combined therapy using cox-inhibitors, such as piroxicam, with mitoxantrone, has 
been shown to provide both anti-cancer and palliative benefits41, with results that 
are superior to using single agent chemotherapy. 
 
 1.3c Radiation Therapy 
 Radiation therapy (RT) is a bladder-sparing alternative to cystectomy, 
although the possibility of acute and late radiation effects limits its use10, 32.  
There are few reports of it being used to successfully treat canine TCC and RT 
alone is often considered inferior to cystectomy, in terms of survival8.  In human 
medicine, RT is used in patients with unresectable or inoperable tumors to 
preserve bladder function10.  In veterinary medicine, it is considered a reasonable 
palliative treatment option to relieve pain or adjuvant treatment option7, but organ 
motion, the need for large margins and the possibility of injury to adjacent 
structures limit curative-intent treatment of intra-abdominal tumors with external 
beam RT42, 43. 
 One of the major obstacles that prevent RT from being a curative 
treatment option is the daily possibility of variations in size, shape and location of 
the bladder and surrounding soft tissue structures8, 15-20.  Further complicating RT 
delivery is the difficulty in visualizing such soft-tissue variations using standard 
megavoltage (MV) portal imaging techniques (Fig. 1.1).  These uncertainties 
require larger treatment margins to ensure coverage of the bladder each day, but 





including the rectum8, 12.  Historical side effects associated with canine bladder 
radiation therapy have included urinary incontinence, cystitis, pollakiuria, and 
stranguria.  Tumor control can be compromised if the dose is decreased to spare 

















Table 1.2 – Average Survival Times with Different T reatment Options 
Treatment  Median Survival  
None < 6 months 
Surgery 125 days26 
RT < 1 year 
Surgery + RT 450 days44 
Chemotherapy + Piroxicam 9-12 months41 












FIG. 1.1  Example of a MV portal radiograph typical ly used for patient set-
up.  Right lateral view of canine abdomen in left l ateral recumbency.  Little 
information about the daily variations in the bladd er and surrounding soft 






 Normal internal physiological movement of the urinary bladder and bowel 
causes daily variations in location8, 15-20.  If organ movement is not accounted for 
in the treatment volume, or the planning target volume (PTV), geographical miss 
is likely to occur, resulting in reduced local tumor control.  Typically, the treatment 
margins are increased to compensate for the size and shape of the bladder and 
uncertainty of its location45.  Increasing the irradiated margins also increases the 
possibility a critical structure, such as the colon, will be irradiated beyond 
tolerance22, 43, leading to unacceptable complications, including colitis, strictures 
and bowel perforation11, 32, 46.  The prescription dose is often lowered in an effort 
to limit the side effects of irradiating nearby sensitive structures, which may result 
in the bladder receiving a non-curative dose. 
 Despite advances in RT treatment technology, little data is available 
describing the daily, interfractional motion characteristics of the bladder, 
especially in veterinary patients.  Most organ motion data has been based on 
human prostate studies22.  Only a few studies have focused on bladder motion 
and bladder motion is hypothesized to be much greater than that of the prostate, 
due to its anatomical characteristics. 
 
1.4 Radiation Biology and Fractionation 
 Ionizing radiation causes cellular damage in multiple ways.  Direct effects 
occur when secondary electrons interact directly with and damage the cellular 
DNA.  Indirect effects occur when the secondary electrons interact with water 





revert back to their original form, or other free radicals, or react with oxygen 
molecules in oxygenated cells to produce peroxides.  Peroxides may cause 
irreparable damage to the chemical structure of the cell.  Indirect methods are 
responsible for approximately two-thirds of the biological damage to cells from x-
rays9.  
 Irradiated cells typically die attempting their next cell cycle or during their 
next mitosis, but can take up to 5 mitoses9.  The damage caused by the 
peroxides is often the cause of this cell death.  However, if the cells are hypoxic, 
these peroxides are not formed as readily and the cells can repair themselves.  
Hypoxic cells are two to three times more radiation resistant than oxygenated 
cells.    
 At any given time, there is a population of cells in the tumor that are not 
well oxygenated and will not respond to irradiation.  The total radiation dose is 
broken into smaller doses, or fractions, and delivered over time to combat this.  
Fractionation allows for a differential response of tumor and normal tissue cells.  
Normal tissues are given the chance to repair between fractions.  Thus, 
administration of radiation in small doses per fraction preferentially spares late 
responding normal tissues.  Tumor cells become reoxygenated and redistribute 
into a different phase of the cell cycle that are more radiosensitive. 
 
1.5 Acute and Late Radiation Effects 
 Regardless of the type of RT or the manner in which it is delivered, a 





control while simultaneously sparing any nearby critical structures9.  During RT 
for bladder cancer, normal tissues such as colon, rectum, urethra, bone, small 
intestine, and spinal cord are included in the radiation field, which puts them at 
risk for the development of acute and/or late effects11, 12, 47.  It is the possible 
toxicity to these critical structures that dictates the limiting dose that can be given 
to the PTV6.   
 Acute effects are most often observed within 10-14 days after the start of 
treatment, may persist throughout the course of treatment, and most often 
subside within 2-3 weeks after treatment has ended9.  Such side effects include 
radiation dermatitis, acute colitis, proctitis, enteritis, and cystitis/urethritis8, 11, 48-50 
(Table 1.3).  They are most certainly uncomfortable for the patient and require 
extra care by the owner and veterinarian.  However, they are rarely life 
threatening and usually resolve with appropriate care, such as anti-inflamatory 
drugs, antibiotics and pain management3, 11-13.  Acute effects are rarely dose-
limiting3, 11, 12. 
 Late effects occur months to years after a course of RT has been given 
and are dose limiting9.  They are caused by damage to the parenchyma and 
connective tissues and are irreversible, often progressive, and can negatively 
impact the quality or length of the patient’s life11, 12.  They can arise directly or 
can be the result of severe radiation injury to acutely-responding tissues, known 
as consequential late effects9.  Late effects seen with bladder cancer RT are 
chronic colitis, proctitis, gastrointestinal perforation, rectal and anal fistulas, 





1.3).  Studies have shown that the number and severity of late effects increases 


































Table 1.3  Acute and Late Effects of Canine Pelvic Irradiation 
Acute Effects  Late Effects  
radiation dermatitis chronic colitis 
acute colitis chronic enteritis 
acute proctitis chronic proctitis 
acute enteritis gastrointestinal perforation 
cystitis/urethritis gastrointestinal stricture 
 urinary bladder fibrosis 
 myelopathy 








1.6 Radiation Therapy Protocols 
 1.6a Standard CT-Based Bony Anatomy Protocol 
 There is a wide diversity of external beam RT treatment devices used in 
veterinary facilities, but the trend over the last few decades has been towards the 
utilization of Cobalt-60 units and linear accelerators2.  Cobalt-60 units utilize 
gamma-rays and linear accelerators utilize x-rays, but both types of devices 
deliver megavoltage (MV) therapy.  Cobalt-60 units have an average energy of 
approximately 1.2 MeV from gamma radiation and a Dmax of 0.5 cm.  Medical 
linear accelerators typically produce bremsstrahlung x-ray spectra from 4 – 25 
MV, with Dmax for a 6 MV unit at 1.5 cm. 
 The typical planning process begins with the patient receiving an original 
planning CT scan with the patient in the treatment position and using any 
immobilization devices required for a reproducible daily set-up.  The planning CT 
is then transferred to a treatment planning system (TPS) where the tumor is 
located and organ contours are defined.  Other volumes of interest are defined 
as required based on the location and extent of the tumor.  The gross tumor 
volume (GTV) (Fig. 1.2, red contour) is the visible or palpable tumor mass that 
can be visualized by imaging techniques, such as on the planning CT.  The GTV, 
plus an added margin to account for any microscopic or subclinical disease, is 
defined as the clinical target volume (CTV) (Fig. 1.2, yellow contour).  The CTV is 
defined as the entire bladder in most bladder cancer cases.  The CTV, plus an 





motion, is defined as the planning target volume (PTV) (Fig. 1.2, green contour).  
The PTV is the radiation target volume.  Critical organs, such as the rectum, are 
defined in the RT planning process in order to avoid them in the radiation plan in 
































FIG. 1.2  Contours drawn on a planning CT to define  the GTV (red), bladder 






 All volumes and organs of interest are contoured on the planning CT and 
a radiation plan developed.  A survey of veterinary radiation therapy facilities 
found that canine bladder protocols range in prescription from 2.25 to 3.2 
Gy/fraction daily, Monday through Friday, for 16-25 fractions with a total dose of 
48-63 Gy to be delivered to the PTV1, 11.  Palliative protocols use larger doses 
per fraction, and are delivered less often. 
 Dogs are anesthetized and positioned for daily treatment in the same 
position as for the planning CT, utilizing the same immobilization and set-up 
devices, as required.  Patient position is verified via radiographic imaging, 
typically portal radiographs2, 51.  The daily position of the patient is aligned to 
match the position during the planning CT utilizing the patient’s bony anatomy 
landmarks or implanted fiducial markers, as seen on the radiograph.  Once the 
patient position is verified, the prescribed plan is delivered to the PTV. 
 
 1.6b CT-Based Soft Tissue Protocol at CSU 
 Currently at CSU, the original planning CT scans for patients are obtained 
using a multislice helical scanner utilizing 2 mm thick slices while the patients are 
in the treatment position.  Planning CT’s are acquired at approximately the same 
time the dogs will be treated each day in order to standardize bladder and rectum 
sizes.  Dogs are allowed to void their bladders in the morning, but defecation is 






 Planning CT images are transferred to a Varian Eclipse TPS.  IMRT plans 
are constructed using the entire bladder volume as the CTV.  Margins from 5-10 
mm are typically added to the CTV to construct the PTV, which becomes the 
target volume.  Multi-leaf collimators (MLC) are used to achieve field shaping and 
dose conformality. 
 Cone beam CT (CBCT) images are acquired immediately prior to each 
daily treatment session using the Varian Trilogy On-Board Imaging (Varian 
Medical Systems, CA, USA) kV X-ray source and digital detection panel mounted 
on the gantry of the linear accelerator, instead of portal radiographs.  The CBCT 
acquires 3D images of the patient’s internal anatomy at 125 kVp and 80 mA.  
Each daily CBCT images the portion of the abdomen containing the bladder and 
can be reconstructed with slice thicknesses ranging from one to 10 mm.  Two 
mm slices were used with a 512  512 reconstruction matrix for this study.  The 
CBCT images are used to characterize the bladder each day and make patient 
positioning adjustments.  CBCT allows for visualization of the bladder each day 
and the patient is able to be positioned based on the daily bladder position 
instead of being based on bony anatomy.  The prescribed dose is delivered to 
the PTV after the patient is set up appropriately. 
 
1.7 Cone Beam Computed Tomography  
 Increasing complexity of RT treatment plans and the ability to deliver more 
conformal doses with techniques such as 3D conformal radiation therapy (CRT) 
and intensity modulated radiotherapy (IMRT) increases the importance of 





help achieve accurate delivery is kilovoltage (kV) cone beam computed 
tomography (CBCT).  CBCT is comprised of a single, cone-shaped x-ray beam 
on one arm of the linear accelerator and a flat panel detector on the other.  The 
arms rotate 360° around the patient one time to acqui re the image volume (Fig. 
1.3).   
 Images are constructed using an algorithm that allows viewing by slice, 
similar to a traditional CT.  Image quality is slightly inferior to a traditional CT 
because the unique geometry of CBCT introduces more scatter which slightly 
reduces contrast and increases noise on the image45.  Despite the increased 
noise, soft-tissue and bony structures are easily visible (Fig. 1.4) and the CBCT 
images can be used to locate structures of interest and assist in patient 
positioning. 
 CBCT is a valuable tool in the imaging of volumetric soft tissue anatomy 
for patient positioning and target verification45.  CBCT improves geometric 
accuracy for advanced treatment delivery and allows for an increase in dose to 














FIG. 1.3  Cartoon depicting CBCT rotation around pa tient (top) and 


























FIG. 1.4  Traditional CT (left) shows higher image quality than CBCT (right) 
due to scatter, however structures of interest are easily visible with CBCT 






1.8 Study Aims 
 Many unique factors regarding canine urinary bladder cancer necessitate 
the treatment of the entire bladder.  Different treatment options exist for this 
malignancy; however treatment outcomes are often less than desirable 
regardless of treatment type.  RT has been no exception. 
 Motion of the bladder and surrounding pelvic organs, as well as 
deformation of the bladder due to differing states of filling, are the dominant 
sources of error in the planning and delivery of RT for canine bladder cancer.  
Use of non-optimal margins to account for this uncertainty compromises patient 
care and adversely affects treatment outcome.  No data is available describing 
the daily motion and position characteristics of the canine bladder to date. 
 The hypothesis of this study was twofold.  We first hypothesized a 
quantification of the daily motion characteristics of the canine urinary bladder 
could be accomplished using retrospective patient data acquired through daily 
CBCT imaging unique to CSU.  The bladder is one of the sites with great 
potential for benefit from imaging technology, providing daily visualization of the 
target prior to treatment52.  We next hypothesized that bladder motion and 
position data could be used to develop an optimal RT protocol that would deliver 
a conformal, curative-intent dose to the bladder while minimizing the dose 
received by the nearby rectum.  A unique study aim was used to address each 
hypothesis.  
 





 Aim 1 of this study addressed our hypothesis that we could use CBCT 
imaging technology to: 
 
1. quantify the daily motion characteristics of the canine urinary bladder in 
three different treatment positions, and 
2. recommend an adequate PTV expansion margin that would ensure 
adequate irradiation of the entire bladder each day, while minimizing 
unacceptable complications due to irradiation of the rectum. 
 
 Quantification of the daily bladder wall position variations experienced by 
the canine urinary bladder on a daily basis with dogs in three possible treatment 
positions was done by making distance measurements on retrospective daily 
CBCT images.  The data from these measurements was then used to determine 
the most advantageous treatment position for canine bladder cancer patients 
receiving external beam RT.  The most advantageous position was that which 
showed the smallest amount of bladder wall variation in six measured directions. 
 A 5, 10 or 15 mm treatment margin was added to the planning CT bladder 
volume, in addition to taking bladder variation measurements.   Sample two-field 
plans using parallel opposed beams were developed that utilized actual, 
retrospective daily positioning images.  Dosimetric data for each plan was then 
examined using the dose volume histogram (DVH) generated by the TPS.  The 





irradiation of the entire bladder each day while minimizing the dose received by 
the rectum. 
 
 1.8b Aim 2 – Optimization of Bladder Cancer Radiati on Therapy  
  using Bladder Motion Data 
 Aim 2 of this study addressed our hypothesis that we could use the 
bladder motion data from Aim 1 to: 
 
1. develop plans and compare dosimetric data for different advanced RT 
techniques, and 
2. develop an adaptive RT (ART) protocol that would optimize the dose 
delivery for canine bladder cancer. 
  
 The bladder motion and treatment setup data from Aim 1 was used to 
create different types of advanced RT plans.  Advanced plan types evaluated 
included an intensity modulated RT (IMRT) plan using bony anatomy registration 
and an IMRT plan using soft tissue registration. The feasibility of an ART plan 
that used a new target volume based on each day’s anatomy was also 
examined.  The dosimetric data for the new plans, as well as the dosimetric data 
from the parallel opposed plans in Aim 1, was compared using DVH’s.  The 
optimal treatment protocol was selected to be the plan that provided the most 
conformal, curative-intent dose to the bladder while simultaneously minimizing 





CHAPTER 2  
CHARACTERIZATION of INTERFRACTIONAL BLADDER VARIATI ONS and 




 2.1a Implications of Non-optimal PTV Margins   
 Organ motion data is an integral part of effectively planning RT for a 
patient, however most studies that have addressed this issue for pelvic irradiation 
have been human prostate studies.  Motion of the prostate, while affected by 
motion of the organs surrounding it, is not affected by filling, unlike the bladder.    
The urinary bladder is a hollow organ that varies in position due to pressure from 
other organs in the pelvis and changes in urine filling of the bladder itself.  Both 
external pressure from surrounding organs and volume changes of the bladder 
may occur simultaneously, resulting in substantial movement of the bladder8, 53.  
In addition, tumors experience intrafractional motion during a treatment session, 
including normal peristaltic motion of the digestive tract. 
 In order to effectively treat canine bladder tumors, the characteristics of 
interfractional bladder variations need to be understood.  A routine practice is to 
add a safety margin around the target volume to reduce the risk of a geographic 
miss however, this may result in unnecessary irradiation of the surrounding 
critical tissues47.  Interfractional bladder variability information is a crucial 





variation is greater than accounted for with the PTV, the prescription dose to the 
CTV may not be achieved and tumor control will be compromised.  If the daily 
bladder motion is much less than accounted for with the PTV, the tolerance dose 
to the normal tissues may be unnecessarily exceeded5, 8.  Currently, it is not clear 
what PTV margins should be used in clinical practice for the treatment of canine 
bladder cancer. 
 
 2.1b Treatment Positions 
 Different methods have been used to deliver an effective dose while 
minimizing colon and rectum irradiation to lessen the morbidity associated with 
bladder RT.  One method used with some success in both human and canine 
patients is surgically-implanted tissue expanders.  Studies have reported fewer 
radiation-induced side effects and lower percentages of bowel in the radiation 
field 42, 54-57.  Tissue expanders create physical separation between the bladder 
and rectum, thus providing a margin that has the potential to allow delivery of 
higher total doses without adverse side effects to the colon42. 
 We hypothesized that optimal choice of patient positioning on the 
treatment couch would improve physical separation of the bladder and rectum 
without the risks of infection from invasive surgery.  The appropriate treatment 
position was investigated as a technique to ameliorate the negative impact of 






 Three different patient positions were chosen for evaluation.  The CSU 
standard of care was to treat bladder and prostate cancer IMRT patients in dorsal 
recumbency upon study initiation (Fig. 2.1, top).  Dorsal position images were 
obtained from patients treated using this initial treatment setup.  The standard of 
care at CSU was changed to treat patients in sternal recumbency during the 
study (Fig. 2.1, middle).  The hypothesis was that the treatment couch adjacent 
to the abdominal wall would allow for a more reproducible treatment set-up from 
day to day by preventing variation in the ventral bladder wall.  Sternal position 
images were obtained from patients using this treatment setup.  The hypothesis 
was that lateral recumbency (Fig. 2.1, bottom) would provide physical separation 
and an easier treatment set up, and preliminary data from this study showed that 
to be the case.  Lateral recumbency became the standard of care for bladder and 
prostate cancer IMRT at the CSUVTH.  Lateral position images were obtained 















FIG. 2.1  Treatment positions evaluated. Dorsal rec umbency (top), sternal 





2.2 Materials and Methods 
 2.2a Patient and Image Selection 
 Subjects for this study were client-owned canine patients undergoing 
standard-of-care fractionated intensity modulated RT (IMRT) at the CSUVTH for 
bladder or prostate cancers.  Images from patients undergoing treatment for 
either disease were used because the organs of interest for this study (bladder 
and rectum/colon) are visible in the images of both types of cases.  This study 
did not alter patient treatment and only retrospectively evaluated image data that 
was collected for patient positioning.  
 The original planning CT scans were obtained using a Picker PQ2000 
(Picker Medical Systems, Cleveland, OH, USA) CT helical scanner with two mm 
thick slices while the patients were in the treatment position.  A vacuum-shaped 
cushion was formed around the patient while in the original position in order to 
reproduce this position each day thereafter, and it was then indexed to the 
treatment couch in the same location for each subsequent treatment. 
 The cone beam CT images were acquired immediately prior to each daily 
treatment with the patient in the treatment position using the Varian Trilogy On-
Board Imaging (Varian Medical Systems, Palo Alto, CA, USA) kV X-ray source 
and detection panel mounted on the gantry of the linear accelerator.  The CBCT 
makes one complete 360-degree rotation around the patient and acquires 3D 
images of the patient’s internal anatomy using a technique of 125kVp and 80 mA.  
Each daily CBCT visualizes the portion of the abdomen containing the bladder 





Two mm slices were used with a 512 × 512 reconstruction matrix for this study.  
In an attempt to standardize bladder and rectum sizes on a daily basis, dogs 
were treated at approximately the same time each day as the planning CT was 
acquired.  Food intake was prohibited until after treatment.  Dogs were taken 
outside to allow them to void their bladders prior to being anesthetized, however 
they were not allowed to defecate at this time.  This allowed a small amount of 
stool to be present in the rectum, as it aids in treatment setup and delivery 
 Images from ten dogs were available for this study. Three dogs were in 
dorsal recumbency, four dogs were in sternal recumbency and three dogs were 
in lateral recumbency.  Fourty four images were daily dorsal CBCT’s (mean = 15 
images per dog), 37 were daily sternal CBCT’s (mean = 9 images per dog), and 
29 were daily lateral CBCT’s (mean = 9 images per dog). 
   
 2.2b Contouring 
 All planning and CBCT images were transferred to the Varian Eclipse 
Treatment Planning System (TPS), software version 8.6.15.  The bladder was 
contoured on each slice of each daily CBCT to include the entire volume 
encompassed by the bladder wall, including the bladder contents, as well as the 
trigone and 2 cm of the urethra caudal to the bladder.  The transverse colon was 
the cranial boundary.  The length of the rectum adjacent to the bladder was also 
contoured and included the entire rectal volume and its contents encompassed 





urinary bladder caudally. All organ contours were drawn on each slice by hand by 
the same investigator (JRN) to ensure consistency. 
  
 2.2c Bony Anatomy Registration 
 The CBCT data sets were registered to the corresponding original 
planning CT image set using bony anatomy as landmarks, such as the spine and 
pelvis using the Varian rigid registration algorithm.  The algorithm uses CT pixel 
values and provides the option for manual adjustment as needed for the bony 
anatomy registration.  All bladder volumes contoured on the daily CBCT scans 
were copied to the original planning CT and in the same planning CT bony 
anatomy frame of reference.  Bony anatomy registration allows for the 
measurement of variations in position of each daily bladder volume with respect 
to the original bladder volume contour (defined on the planning CT). 
 
 2.2d Bladder Variation Measurements 
 The urinary bladder is a hollow organ and there is the possibility that each 
wall can move independently8, so measurements were taken in the right, left, 
dorsal, ventral, cranial, and caudal directions.  All measurements were taken 
relative to a single constant reference point that was determined from the 
planning CT (Fig. 2.2).  This reference point was placed at the 3D center of mass 
of the bladder volume as defined on the planning CT.  Once a point was defined 
for each patient, it remained constant for all subsequent measurements of 





 Measurements were made from the reference point in each of the six 
directions to the bladder wall’s maximum displacement in that direction (Fig. 2.2).  
The entire bladder volume was considered, not simply each slice, to define a 
maximum displacement in one of the measured directions.  To account for 
variations in dog size between different patients, daily positions of the bladder 
wall were compared to the bladder wall position on the day of the planning CT.  
The absolute displacement of the bladder wall from the reference point for each 
day was divided by the original bladder wall displacement from the reference 













FIG. 2.2  Measurements were made from the center of  mass of the bladder 
(TX ISO Bony) to the maximum bladder wall displacem ent in each of six 
directions.  Axial view of patient showing how meas urements were made in 
the right, left, dorsal and ventral directions (top ).  Sagittal view of patient 
showing how measurements were made in the cranial a nd caudal 






 2.2e Parallel Opposed Treatment Plan Construction 
 Three different sample PTV structures were constructed for each dog by 
adding uniform 5 mm, 10 mm, or 15 mm margins to the original bladder volume 
structure, or the CTV, that was contoured on the planning CT (Fig. 2.3).   
 A standard plan was developed for each of the three PTV margins and 
applied to the images from each dog.  The standard plan used for each dog 
consisted of two equally-weighted, conformal, right- and left-lateral parallel 
opposed fields that delivered 54 Gy in 20 fractions of 2.7 Gy with 10 MV photons.  
These plans were developed to theorize delivery based on location of anatomical 
structures in planning CT images.  Plans were developed and analyzed as if they 
were to be delivered, however none of the plans were delivered clinically to the 
patients.  Only computer-generated dosimetric models were analyzed.  This dose 
scheme was chosen based on studies that showed administration of doses per 
fraction greater than 2.7 Gy increases the risk of late effects associated with the 
colon11, 12.  Studies indicate that smaller doses per fraction may result in fewer or 
less severe acute effects with a subsequent reduction in consequential late 
effects11.   
 Standard plans were prescribed to be delivered isocentrically with 100% of 
the prescription dose delivered to the geometric isocenter of the PTV.  Field 
shaping, optimized for each PTV expansion, was achieved with multileaf 
collimators to simulate conventional blocking.  The standard plans were improved 





TPS (Fig. 2.4).  The dose distribution for each of the three PTV expansion plans 















                      
FIG. 2.3  Example of PTV expansions based on the pl anning CT bladder 
volume (CTV) for a dog in right lateral recumbency.   Axial (top), coronal 














FIG. 2.4  Sample parallel opposed plan for dog in r ight lateral recumbency 
showing isodose lines and original bladder contour (CTV).  The same plan 






 2.2f DVH Evaluation 
 The DVH showing the dose distribution of the PTV and the other organs of 
interest was calculated by the treatment planning system and was used to decide 
the acceptability of a treatment plan.  DVH-derived information, like the dose to a 
given fractional volume, is often used as a measure of the quality of a dose 
distribution58.  The ultimate goal of RT is to ensure that the target receives 
accurate and adequate dose coverage, while the dose to the critical structures is 
kept as low as possible23. 
 
 2.2g Statistics 
 Variations in bladder wall position relative to planning CT bladder wall 
position in each of the six directions were compared between dogs in lateral, 
sternal and dorsal recumbency by examining the standard deviations.  A mixed-
model ANOVA was used with position as a fixed factor between dogs to 
investigate differences between positions in each of the six directions.  Statistical 
significance was assumed at P < 0.05.    
 Mean changes in dose to the bladder and rectum were compared between 
dogs in lateral, sternal and dorsal recumbency.  A mixed-model ANOVA was 
used with position as a fixed factor between dogs to investigate differences in 
dose between the three positions.  Statistical significance was assumed at P < 
0.05. 
 All statistical analysis was performed using SAS statistical software v. 10.0 






 2.3a Bladder Variations 
 The CBCT scans show a great amount of positional variation of the 
bladder on a daily basis in all three treatment positions.   However, based on 
standard deviation (SD), the least amount of variation was seen in five out of the 
six directions for dogs in lateral recumbency.  Dogs in lateral recumbency 
showed the least amount of bladder wall variation in the right (SD = 15.1%), left 
(SD = 20.0%), dorsal (SD = 20.5%), cranial (SD = 21.6%), and caudal (SD = 
11.8%) directions when compared to the dorsally and sternally recumbent dogs.  
Table 2.1 summarizes the data. Bladder wall motion data are expressed as 
means, with ranges following in parentheses, ± standard deviation, for each of 
the six directions in each treatment position.  Dogs in lateral recumbency showed 
a statistically significant difference in variability of the right bladder wall (P = 0.04) 
and of the caudal bladder wall (P = 0.005) when compared to dogs in dorsal or 
sternal recumbency.  There was no statistical significance between treatment 
position and variability of bladder wall position in any other directions. 
Based on the CBCT image data for dogs in dorsal recumbency, the mean 
percentage of right  bladder wall variation was 100.6% (range, 46.6% - 161.7%) 
± 24.0%; mean percentage of left bladder wall variation was 87.3% (range, 
46.9% - 164.87%) ± 24.3%; mean percentage of dorsal bladder wall variation 
was 105.5% (range 65.5% - 175%) ± 23.3%; mean percentage of ventral bladder 
wall variation was 79.6% (range 20.9% - 158.1%) ± 24.4%; mean percentage of 





percentage of caudal bladder wall variation was 98.5% (range, 58.3% - 131.8%) 
± 14.0%. 
 For dogs in sternal recumbency, the mean percentage of right  bladder 
wall variation was 90.7% (range, 38.7% - 121.4%) ± 15.7%; mean percentage of 
left bladder wall variation was 96.9% (range, 32.1% - 139.7%) ± 23.7%; mean 
percentage of dorsal bladder wall variation was 110.4% (range 38.7% - 144.2%) 
± 25.6%; mean percentage of ventral bladder wall variation was 69.6% (range 
3.0% - 113.3%) ± 33.1%; mean percentage of cranial bladder wall variation was 
142.2% (range 50.0% - 316.7%) ± 82.2%; mean percentage of caudal bladder 
wall variation was 93.1% (range, 62.5% - 122.2%) ± 14.7%. 
 The CBCT image data for laterally recumbent dogs showed that the mean 
percentage of right  bladder wall variation was 76.0% (range, 58.4% - 121.3%) ± 
15.1%; mean percentage of left bladder wall variation was 101.0% (range, 50.8% 
- 140.8%) ± 20.0%; mean percentage of dorsal bladder wall variation was 91.7% 
(range 42.9% - 131.5%) ± 20.5%; mean percentage of ventral bladder wall 
variation was 105.8% (range 65.7% - 193.2%) ± 28.6%; mean percentage of 
cranial bladder wall variation was 83.4% (range 29.4% - 115.7%) ± 21.6%; mean 
percentage of caudal bladder wall variation was 81.2% (range, 50.0% - 105.8%) 
± 11.8%.  
 
  



















 Mean (Range) Std Dev Mean (Range) Std Dev Mean (Range) Std Dev 
Right   76.0 (58.4-121.3) 15.1    100.6 (46.6-161.7) 24.0   90.7 (38.7-121.4) 15.7 
Left 101.0 (50.8-140.8) 20.0      87.3 (46.9-164.9) 24.3   96.9 (32.1-139.7) 23.7 
Dorsal   91.7 (42.9-131.5) 20.5 105.5 (65.5-175) 23.3 110.4 (38.7-144.2) 25.6 
Ventral 105.8 (65.7-193.2) 28.6      79.6 (20.9-158.1) 24.4 69.6 (3.0-113.3) 33.1 
Cranial   83.4 (29.4-115.7) 21.6      65.3 (0.1-145.45) 32.1 142.2 (50.0-316.7) 82.2 
Caudal   81.2 (50.0-105.8) 11.8      98.5 (58.3-131.8) 14.0   93.1 (62.5-122.2) 14.7 
a. Patient treatment positions. 
b. Directions of bladder wall displacement relative to the common reference point. 
c. Mean, range and SD calculated from data from 3 dogs, 29 total CBCT images (mean = 9 images per dog). 
d. Mean, range and SD calculated from data from 3 dogs, 44 total CBCT images (mean = 15 images per dog). 





 2.3b PTV Margins 
 The application of uniform 5, 10 and 15 mm margins to the planning CT 
bladder volume resulted in different dose distributions for each of the three 
treatment positions.  Bladder dose was evaluated by using the DVH generated 
by the sample plan and determining the percentage volume of the bladder that 
received at least 95% of the prescribed dose.  Adequate dose delivery to the 
bladder volume (CTV) is achievable in all three treatment positions, based on our 
criteria for this study (95% of prescribed dose to CTV).  No statistically significant 
difference was found in bladder dose between the treatment positions.   
Rectal dose was evaluated by determining the absolute volume (cc) of the 
rectum that received at least 100% of the prescribed dose.  Mean dose to the 
rectum was lowest for dogs in lateral recumbency; however, there was no 
statistical difference in rectal dose found between the three treatment positions.  
Table 2.2 summarizes this data.  Dose coverage of bladder and rectal volumes 
are expressed as means, with ranges following in parentheses ± standard 
deviation.  
 When the uniform five mm margin was applied to the bladder volume, 
dogs placed in dorsal recumbency showed 95% of the prescription dose to cover 
a mean bladder volume percentage of 91.1% (range, 54.6-98.7) ± 8.8% with 
100% of the prescription dose being delivered to a mean rectal volume (cc) of 
10.7 (range, 0.1-53.1) ± 11.3 cc.  Dogs in sternal recumbency showed 95% of 
the prescription dose to cover a mean bladder volume percentage of 97.1% 





a mean rectal volume (cc) of 11.6 (range, 0.8-27.6) ± 7.4 cc.  Dogs in lateral 
recumbency showed 95% of the prescription dose to cover a mean bladder 
volume percentage of 93.0% (range, 81.3-99.8) ± 4.5% with 100% of the 
prescription dose being delivered to a mean rectal volume (cc) of 7.0 (range, 0.0-
36.1) ± 7.9 cc.   
 For the uniform 10 mm margin, dogs placed in dorsal recumbency showed 
95% of the prescription dose to cover a mean bladder volume percentage of 
96.0% (range, 66.2-99.3) ± 6.2% with 100% of the prescription dose being 
delivered to a mean rectal volume (cc) of 14.2 (range, 0.4-63.9) ± 12.2 cc.  Dogs 
in sternal recumbency showed 95% of the prescription dose to cover a mean 
bladder volume percentage of 98.0% (range, 95.9-100.0) ± 1.3% with 100% of 
the prescription dose being delivered to a mean rectal volume (cc) of 17.4 
(range, 3.7-35.5) ± 9.3 cc.  Dogs in lateral recumbency showed 95% of the 
prescription dose to cover a mean bladder volume percentage of 98.4% (range, 
87.0-99.9) ± 2.8% with 100% of the prescription dose being delivered to a mean 
rectal volume (cc) of 13.4 (range, 1.0-52.1) ± 9.8 cc. 
 When the 15 mm margin was applied, dogs placed in dorsal recumbency 
showed 95% of the prescription dose to cover a mean bladder volume 
percentage of 97.6% (range, 77.0-100.0) ± 4.2% with 100% of the prescription 
dose being delivered to a mean rectal volume (cc) of 28.1 (range, 1.0-79.1) ± 
14.1 cc.  Dogs in sternal recumbency showed 95% of the prescription dose to 
cover a mean bladder volume percentage of 99.4% (range, 97.4-100.0) ± 0.7% 





of 34.8 (range, 14.9-69.9) ± 13.2 cc.  Dogs in lateral recumbency showed 95% of 
the prescription dose to cover a mean bladder volume percentage of 99.4% 
(range, 93.3-99.9) ± 1.2% with 100% of the prescription dose being delivered to a 
mean rectal volume (cc) of 22.4 (range, 5.0-71.0) ± 12.4 cc.  
 
  




















            5 mm   93.0 (81.3-99.8)   4.5   91.9 (54.6-98.7)  8.8    97.1 (94.2-100.0) 2.0 
     10 mm   98.4 (87.0-99.9)   2.8   96.0 (66.2-99.3)  6.2    98.0 (95.9-100.0) 1.3 




            5 mm   7.0 (0.0-36.1)   7.9 10.7 (0.1-53.1) 11.3 11.6 (0.8-27.6) 7.4 
     10 mm 13.4 (1.0-52.1)   9.8 14.2 (0.4-63.9) 12.2 17.4 (3.7-35.5) 9.3 
     15 mm 22.4 (5.0-71.0) 12.4 28.1 (1.0-79.1) 14.1   34.8 (14.9-69.9) 13.2 
a. Patient treatment positions. 
b. Mean % of the CTV volume that received at least 95% of the prescribed dose. 
c. Mean rectal volume, in cc, that received at least 100% of the prescribed dose. 
d. Mean, range and SD calculated from data from 3 dogs, 29 total CBCT images (mean = 9 images per dog).  
e. Mean, range and SD calculated from data from 3 dogs, 29 total CBCT images (mean = 9 images per dog). 







2.4 Discussion of Results 
 2.4a Characterization of Bladder Variations 
 A treatment plan is based on the pre-treatment imaging in most cases, 
with the treatment volumes being based on the pre-treatment bladder volume, 
location and shape.  Unfortunately, these parameters are not always the same 
from day to day and such uncertainties can affect the treatment outcome.  Based 
on the measurements from the daily CBCT data, we determined that the most 
optimal treatment position would be the one that would allow for the least amount 
of variation on a daily basis, which allows for the most reproducible treatment 
scenario each day. 
 Positioning in lateral recumbency allows for the least amount of bladder 
variation on a daily basis and results in the most reproducible treatment scenario 
each day.  This was based on the smallest SD in five of the six directions for 
dogs in lateral recumbency, and was found to be statistically significant for the 
right (P = 0.04) and caudal (P = 0.005) bladder walls (Table 2.1). 
 These findings emphasize that, regardless of treatment position and 
efforts to standardize bladder volume through regular voiding, there can be 
substantial bladder wall movement from day to day.  It is important for these 
values to be as consistent as possible because similarity of the daily bladder wall 
position to the original planning CT bladder wall position allows more accurate 
delivery of the dose to the bladder and minimizes dose to the surrounding 
tissues, resulting in fewer unacceptable complications.  Although the bladder wall 
variations were not found to be statistically less for some of the directions 





to be more reproducible from day to day when dogs are placed in lateral 
recumbency. 
 Minimal variation from the planning CT bladder wall position occurred in 
the caudal direction in all three treatment positions, with the lateral, dorsal and 
sternal positions all experiencing similar amounts of daily variation (SD = 11.8%, 
14.0% and 14.7%, respectively) (Table 2.1) (Figs. 2.5A, B, C).  This limited 
variation is most likely due to the fact that the caudal aspect of the bladder is 
continuous with the urethra and is limited in the amount of motion it can 
experience. 
 Human studies have found bladder motion to be most pronounced in the 
cranial and anterior directions8, 47, and in this study of canine bladder wall 
variations, motion was found to be most pronounced in the cranial and ventral 
directions.  There was a large amount of variation in the daily bladder wall 
position from the planning CT bladder wall position in the cranial direction for 
dogs in sternal recumbency (142.2% ± 82.2%)  (Fig. 2.5).  We have attributed 
this to the fact that, when the dogs are placed in this position, the treatment 
couch limits the variation in the ventral direction, the spine limits the variation in 
the dorsal direction and the urethra limits the variation in the caudal direction, so 
the bladder wall position varies in the cranial direction with daily changes in 
volume.  We hypothesize that this may also be the reason that dogs in lateral 
recumbency show a significantly smaller amount of variation in bladder wall 
position in the right direction and show the greatest amount of variation in the 





treatment couch.  The larger amount of variation observed by the ventral wall 
would not be limited by physical restriction and could freely change position as 
the position or volume of the bladder changed.    
 Of the six directions, laterally recumbent dogs showed the largest SD, and 
largest amount of variation in the ventral direction (Table 2.1) (Fig. 2.5A).  When 
dogs are in lateral recumbency, the ventral bladder wall has no physical 
restriction to motion and, like the cranial direction, the bladder moves freely in 
this direction as it fills.  The ventral direction was the direction with the second-
highest amount of bladder wall variation for dogs in dorsal recumbency (79.6% ± 
48.8%) (Fig. 2.5B) and dogs in sternal recumbency (69.6% ± 66.2%) (Fig. 2.5C). 
 A solution to compensate for the pronounced bladder wall motion in the 
cranial and ventral directions would be to asymmetrically increase the PTV 
margin in the cranial and anterior directions.  Another option would be to use 
adaptive RT to account for these shape changes for each individual patient on 



















Fig. 2.5A  Bladder wall variations for dog in right  lateral recumbency.  Dogs 
in lateral recumbency showed the greatest amount of  bladder wall variation 
ventrally and cranially.  Lateral recumbency allows  for the least amount of 




Fig. 2.5B  Bladder wall variations for dog in dorsa l recumbency.  Dogs in 
dorsal recumbency showed the greatest amount of bla dder wall variation in 




Fig. 2.5C  Bladder wall variations for dog in stern al recumbency.  Cranial 
variations were largest in this position due to the  restricted bladder wall 






 2.4b Evaluation of Patient Position and PTV Expans ions  
 Dose volume histograms were used to analyze the dosimetric data for 
each PTV expansion in each treatment position (Figs. 2.6, 2.7, 2.8).  Dogs in 
lateral recumbency showed the least amount of variation in bladder wall position 
and subsequently showed the best dose distribution for each of the three PTV 
expansions using parallel opposed RT plans.  This information will prove to be 
helpful in choosing the best treatment set-up scenario for bladder cancer patients 
at all veterinary radiation therapy facilities. 
 Based on the practices common in our clinic we chose to assess the 
percent volume of the bladder receiving 95% of the 54 Gy prescription dose and, 
as expected, found each increasing PTV expansion to provide increasing bladder 
coverage for all three treatment positions (Table 2.2).  No statistical differences 
were found between treatment positions for dose coverage to the bladder CTV.   
The goal was to determine the PTV expansion that would maximize the 
percentage of the bladder volume receiving 95% of the prescription dose while 
simultaneously minimizing the rectal volume that would receive 100% of the 
prescription dose.  Studies in humans receiving abdominal or pelvic irradiation 
are conflicting in their conclusions about volume effects and late gastrointestinal 
radiation, and the criteria used to define large versus small volumes differs 
substantially in these studies.  A similar study in rats was not able to show a 
correlation of field size or length of colon in the field to severity of late effects59.  
However, in a study of pelvic irradiation in dogs, the entire rectal circumference 





effects11.  Thus, we decided to examine the rectal volume receiving the total 
dose.  The lateral treatment position best minimized dose to the rectum using the 
5, 10 and 15 mm expansions, with only 1.9, 5.4 and 16.1 cc, respectively, 
receiving the full prescription dose.  Limiting the dose to the rectum via lateral 
positioning may prove to be clinically significant, although not statistically 
significant, as previous studies have found a correlation between fraction size 
and adverse effects11, as well as support using more conformal techniques in 
order to reduce dose to sensitive normal tissues and reduce complication rate12. 
Although each clinic will have unique and specific planning goals with 
respect to maximum rectal dose allowed and bladder coverage critera, an ideal 
expansion provides a good compromise between adequate bladder coverage 
while minimizing rectal dose.   
PTV optimization was performed by simultaneously plotting the average 
percentage of the bladder volume that received less than 95% of the 54 Gy 
prescription dose and the average rectal volume (cc) that received the 54 Gy 
prescription dose or greater for each of the PTV expansions.  One graph was 
produced for each of the three treatment positions (Figs. 2.9, 2.10, 2.11).  
Optimal expansion would be the intersection of the two lines in each plot.  The 10 
mm expansion offers the best compromise of bladder coverage and minimal 











Fig. 2.6  Lateral position dose volume histograms f or 5(top), 10(middle) and 










Fig. 2.7  Dorsal position dose volume histograms fo r 5(top), 10(middle) and 










Fig. 2.8  Sternal position dose volume histograms f or 5(a), 10(b) and 15(c) 














Fig. 2.9  Graph for dogs in dorsal recumbency showi ng average percentage 
of bladder volume that receives less than 95% of 54  Gy prescription dose 
(left axis, blue line) and average rectal volume (c c) receiving 54 Gy 
prescription dose or greater (right axis, red line)  for 5, 10 and 15 mm PTV 


































Fig. 2.10  Graph for dogs in sternal recumbency sho wing average 
percentage of bladder volume that receives less tha n 95% of 54 Gy 
prescription dose (left axis, blue line) and averag e rectal volume (cc) 
receiving 54 Gy prescription dose or greater (right  axis, red line) for 5, 10 




































Fig. 2.11  Graph for dogs in lateral recumbency sho wing average 
percentage of bladder volume that receives less tha n 95% of 54 Gy 
prescription dose (left axis, blue line) and averag e rectal volume (cc) 
receiving 54 Gy prescription dose or greater (right  axis, red line) for 5, 10 
























 The overall dose distribution seen on the DVH’s for the lateral dogs is 
optimal of the three positions (Fig. 2.6).  In addition to the lateral treatment 
position experiencing the smallest amount of overall bladder wall variation, 
another possible explanation for this was noticed while constructing the contours 
on the daily CBCT images.  The bladders of dogs in dorsal or sternal 
recumbency, as noted in the above section, are restricted in movement in certain 
directions due to the treatment couch or another anatomical structure, the most 
noticeable of these being the rectum.  Despite efforts to produce the same 
bladder and rectal volumes from day to day, there are days when the rectal 
volume is larger than the rectal volume of the planning CT.  This causes the 
rectum to displace the bladder where they are closest and cause a deformation 
in the bladder that differs from the bladder shape on the original planning CT 
(Fig. 2.12).  A substantial portion of the rectum then occupies the same space 
that was previously designated in the treatment plan as the bladder.  Since the 
planning CT volumes are used to produce the RT plan, the rectum is directly 
irradiated on the days when it displaces the bladder.  This phenomenon was not 
noticed with the dogs positioned in lateral recumbency, as there is less variation 
in the motion of the rectum and the bladder is able to move away from the 
rectum, often producing physical separation between the two structures, thus 














               
 
FIG. 2.12  Bladder deformation experienced by dogs in sternal or dorsal 
recumbency is not noticed in dogs in lateral recumb ency. (a) CBCT data 
fused onto the planning CT shows that large rectal volumes can deform the 
bladder and cause the daily bladder shape to differ  from the original 
planned shape that will be irradiated.  (b) Lateral  CBCT data fused onto 
planning CT does not show this phenomenon, as the b ladder and rectum 






CHAPTER 3  
IMRT, IGRT and ART 
 
 
3.1 Introduction to Advanced Techniques in Radiatio n Therapy   
 Techniques such as 3D conformal RT (CRT) and intensity modulated RT 
(IMRT) were developed to improve upon traditional, non-CT based treatment 
setups with large radiation fields, uniform-intensity beams, and a high probability 
of radiation-related side effects.  Advanced RT techniques are based on 3D 
anatomic information and use dose distributions that conform as closely as 
possible to the target volume (Fig. 3.1).  Conformality allows for a higher dose to 
be delivered and minimizes the probability of normal tissue complication.  
Conformal radiotherapy offers the greatest advantage at sites, such as the 
bladder, where existing local control is limited by the collateral dose to nearby 
normal structures5, such as the rectum. 
 Despite the advantages of using a conformal RT technique, there are 
some potential obstacles.  Accurate assessment, localization and delivery are 
vital to improve tumor control and reduce normal tissue toxicity in conformal 
radiotherapy60.  Organ motion and setup errors provide possibilities for the tumor 
target to vary in position each day, and must be accounted for with an adequate 
PTV margin.  In addition, the higher doses that are often used with these types of 
therapies need to be accurately targeted and delivered to the tumor each day to 









Fig. 3.1  Colorwash dose distribution for (top) par allel opposed, and 
(bottom) IMRT treatment plans. IMRT delivers a more  conformal dose to the 







 3.1a Intensity Modulated Radiation Therapy (IMRT)  
 Intensity modulation is the process of modulating the beam intensity 
profiles so that a specific planning goal is met.  This can be accomplished with 
wedges or, in the case of IMRT, multi-leaf collimators (MLC).  IMRT is an 
advanced form of CRT that delivers non-uniform fluence to the target from 
several different beams with the goal being delivery of a composite, conformal 
dose distribution.  Each beam is weighted so as to achieve the final dose 
distribution, as predetermined by the treatment planning system (TPS).  The TPS 
determines the optimum intensity modulation, as decided through inverse 
planning, and limits the dose to the surrounding normal tissue.   
 The computer-controlled MLC shape the field in a static or dynamic 
delivery, or some combination of the two, to achieve the conformal dose in IMRT.  
In the static delivery method, the leaves move to shape each sub-field, the beam 
is turned on and then switched off while the leaves position themselves into the 
next sub-field position.  This is also sometimes known as step-and-shoot 
delivery.  With the dynamic delivery method, the leaves simultaneously sweep 
from one side to the other and the radiation is delivered as the leaves are 
moving.  This method is sometimes known as the sliding window method.  The 
gantry rotates to the next position and the next beam is delivered.  This process 
is repeated until all beams have been delivered and the total fractional dose has 
been delivered. 
 IMRT delivery has provided an effective way to shape dose distributions to 





volume.  Dose conformality is essential to escalate the radiation dose in order to 
improve the outcome of bladder RT and avoid increased normal tissue adverse 
effects52.  IMRT is superior to CRT with respect to sparing of the bowel61.  In 
human studies, IMRT has demonstrated a reduction in both acute and late 
radiation morbidity compared to conformal techniques21, 23. 
 Despite the success rates seen in human medicine, IMRT is still a 
relatively uncommon practice in veterinary medicine, especially for the treatment 
of canine bladder cancer.  A very modern, late model linear accelerator or 
tomotherapy unit is needed to deliver IMRT and is not readily available to all 
veterinary facilities.  Another complicating factor is the need for a better 
understanding of the motion characteristics of the canine pelvic organs in order 
to precisely deliver the higher radiation doses used with IMRT and to avoid 
delivering these high doses to nearby critical structures.  If these motion 
characteristics are better understood, it may be possible to achieve a success 
rate similar to that seen in human medicine using IMRT for canine bladder 
cancer patients.  
 
 3.1b Image Guided Radiation Therapy (IGRT) 
 A fundamental principle of RT is that a successful treatment outcome 
requires accurate alignment of the treatment field to the target tissue volume5, 
especially for highly-conformal methods such as IMRT, which produce such 
steep dose gradients outside of the PTV.  Therefore, adequate visualization of 





improving RT.  However, during the course of radiotherapy, target volumes can 
change position due to motion from surrounding internal organs and 
physiological processes.  The conformal dose distributions and steep dose 
gradients generated around target volumes when using IMRT require an 
accurate, reproducible treatment setup with monitoring and verification at the 
time of treatment set-up to prevent a geographic miss or over-irradiation of 
nearby normal tissues.  Accuracy in localization becomes even more important 
with the delivery of high doses each day using IMRT 62.  It therefore seems 
advantageous to use image guidance to safely deliver such treatments. 
 Image guided RT (IGRT) is the use of imaging technology to assist in the 
delivery of RT, such as IMRT, to the appropriate target volume.  Different types 
of imaging can be used, such as kV orthogonal, MV portal or CBCT.  The images 
are acquired after the patient has been placed in the daily treatment position and 
immediately prior to the delivery of that daily RT fraction.  The daily images are 
then used to make position adjustments to properly align the patient anatomy to 
the linac isocenter.  The planned dose is not changed from day to day, however 
minor position adjustments enable the daily target volume to be better aligned to 
match the treatment plan than if image guidance was not utilized.  The images 
help to more accurately localize the target volume and avoid irradiating the 
surrounding tissues.  Increased accuracy in tumor localization also allows for a 
decrease in the PTV margins due to decreased uncertainty regarding the 





decreased PTV margin lowers the total volume irradiated and the possibility of 
radiation-induced side effects. 
 Volumetric imaging of the area of interest is becoming an integral part of 
IGRT, with many studies reporting significant improvements in the visibility of 
anatomic structures, soft tissues in particular, compared with megavoltage portal 
imaging63.   3D imaging systems, such as cone beam computed tomography 
(CBCT), can improve daily setup and therefore increase the accuracy of RT 
delivery.  Kilovoltage (kV) CBCT can be mounted on the linear accelerator gantry 
and permit the volumetric position verification of the tumor volume and 
surrounding organs at risk, relative to the treatment geometry, immediately prior 
to treatment.  Thus, CBCT systems allow online correction of patient setup 
errors, immediately prior to initiation of RT64.  CBCT allows the treatment of 
tumors that were not easily or effectively treated before by enabling accurate 
patient setup. 
 
 3.1c Adaptive Radiation Therapy (ART) 
 The emergence of IGRT and newer imaging technologies has made the 
improvement of many types of RT possible by allowing visualization of the tumor 
immediately prior to treatment while the patient is in the treatment position and 
allowing for adjustments to better target the tumor volume.  However, some 
tumors, such as bladder tumors, require the treatment of volumes that not only 
change position, but can change shape and volume as well.  A standard RT 





each day that was based on the original planning CT volumes and their positions.  
If the daily target volume lies outside of the original PTV, there is the risk for 
geographic miss and lowered tumor control.  If the daily target volume is much 
smaller than the original treatment volume, there is the risk for irradiation of the 
normal tissue that is nearby and an increase in probability of subsequent 
radiation-induced side effects.  An adaptive radiotherapy (ART) protocol that 
reviews daily images in order to implement changes and adapt the treatment 
plan before delivery will facilitate visualization and assessment of both setup and 
random daily organ movement and volume variations. 
 ART, sometimes referred to as dynamic adaptive RT (DART), is a 
technique that re-optimizes RT throughout the course of the treatment on an 
individual patient basis53.  It uses daily images, acquired at the time of each 
treatment, to develop and deliver a new RT plan each day, based on that day’s 
anatomy.  ART can occur daily (online), during treatment (real time), or it can 
occur between fractions (offline).  Offline adaptation takes place between 
treatment fractions based on new information that can be used to adapt 
treatments for gradual changes in patient or tumor anatomy, physiology, or 
setup. Real-time adaptation involves techniques such as respiratory gating to 
gate the beam during treatment to account for internal organ motion, such as 
lung motion during the breathing cycle. Treatment machine parameters are 
adapted in real time to conform to the patient anatomy in real time. Online 
adaptation updates the treatment parameters based on new daily information to 





the patient alone cannot correct.  Online adaptation ensures that the treatment 
objectives are continuously met despite changes in the patient5 or position of the 
target.  
 ART is superior to traditional CT-based treatment planning because 
traditional planning utilizes a single image data set of the patient, which may not 
be an accurate representation of anatomic shape and position on each day of a 
prolonged course of treatment. Uncertainties are typically incorporated into the 
PTV margins when a single CT data set is used for planning and result in a larger 
irradiated volume.  The ART strategy leads to a substantial reduction in treatment 
volumes and improved targeting of those volumes when compared with 
conventional strategies in human studies6.  The ART approach can reduce 
toxicity and allows for the possibility of dose escalation, which could lead to 
improvement of RT treatment outcomes.  ART could be especially useful for the 
treatment of canine bladder cancers, as the tissue volume and location can vary 
from day to day. 
  
3.2 Materials and Methods 
 3.2a Patient Selection 
 The bladder motion and PTV expansion data from the first aim of this 
study showed that dogs placed in lateral recumbency had the most reproducible 
setup and best dose distribution on a daily basis.  Thus, image data used to 
construct the following treatment plans were from four dogs positioned in lateral 





received daily CBCT scans for positioning purposes.  Twenty CBCT data sets 
were available for each patient, for a total of 80 CBCT data sets.  Each type of 
plan was constructed using the data sets from all four dogs. 
 
 3.2b Bony Anatomy Registration  
 Owing to the fact that many human studies have found that IMRT reduces 
both acute and late radiation morbidity compared to conformal techniques21, 23, 
the possibility for duplicating human results in canine bladder cancer patients 
was explored.  Daily CBCT images were registered to the planning CT for each 
of the four laterally recumbent dogs using a bony anatomy registration technique 
(Section 2.2c) and dose distributions evaluated for each daily bladder volume.  
The daily bladder and rectal contours were copied from each daily CBCT image 
to the original planning CT image which shared the same bony anatomy frame of 
reference. 
 IMRT plans for each of the four dogs were then constructed by adding a 
uniform 5 mm PTV margin to the original planning CT bladder volume.  This 
smaller margin was examined for this technique because it was hypothesized 
that the more conformal techniques would allow for a reduction in the PTV 
volume in order to spare the nearby healthy tissues.  A typical 7-field IMRT 
technique (0, 51, 102, 153, 204, 255, and 306-degree field gantry angles) was 
used with the field intensity modulated by the MLC during sliding window 
delivery.  The TPS uses an iterative optimization to focus dose on the PTV and 





was isocentrically prescribed to the PTV using 6 MV photons.  Dosimetric data 
was generated by the TPS and displayed on the DVH for plan review.  The dose 
distribution for each daily bladder and rectal volume was evaluated by DVH. 
 
 3.2c Soft Tissue Registration 
 A different type of registration based on soft tissues can be used to 
improve the delivery of RT to tissues that experience a wide range of motion and 
shape changes.  The CBCT images, after being transferred to the TPS, were 
registered to the planning CT image set.  Registration was accomplished using a 
soft tissue registration.  This registration technique does not use bony landmarks 
as reference points, but rather matches soft tissue organs of interest.  For the 
purposes of this study, the bladder structure from each daily CBCT was matched, 
as close as possible, to the original bladder structure from the planning CT.  The 
bladder volumes contoured on the CBCT scans were copied to the planning CT 
so they would be in the same soft tissue frame of reference, based on the 
bladder position for each day.   
 Soft tissue image guided registration takes organ motion into account for 
the subsequent treatment delivery and allows for a more accurate fit of the daily 
bladder volume to the original PTV (Fig. 3.2) by allowing the bladder to be 
“chased” using CBCT images.  Accuracy of treatment delivery is crucial to 
effective RT, and especially when delivering high radiation doses with techniques 











FIG. 3.2  Planning CT with daily CBCT bladder volum e copied after 
registration.  Bony anatomy registration (top) posi tions patient based on 
bony structures, but does not take into account org an motion and 
produces a discrepancy in bladder volume positions.   Soft tissue 
registration (bottom) is based on the bladder itsel f and provides better 






 3.2d Soft Tissue Registration Plan Construction 
 The use of IMRT to deliver high doses with steep dose gradients requires 
accurate localization of the daily target and delivery of the radiation62.  The ability 
to use CBCT for localization of the bladder and soft tissue registration to target 
the IMRT dose makes curative IGRT for canine bladder cancer a possibility.   
 The CBCT data sets for each of the four dogs in lateral recumbency were 
registered to the planning CT using a soft tissue registration method, in order to 
evaluate the dose distributions for the daily bladder volumes.  The daily bladder 
and rectal contours were copied to the planning CT and now utilized the same 
soft tissue frame of reference. 
 The IGRT treatment plans for each of the four dogs were then constructed 
using the same 5 mm PTV expansion and 7-field IMRT technique as used for the 
bony anatomy registration, IMRT plans (Section 3.2b).  Again, the DVH displayed 
the dosimetric data generated by the TPS and was used for evaluation of the 
IGRT plans. 
 
 3.2e ART Plan Construction 
 IGRT with CBCT provides the ability to clearly image the internal anatomy 
each day prior to treatment and to target the correct volume.  The radiation 
treatment plan could then be modified each day based on the imaging 
information and the development of an ART plan to treat canine bladder cancer. 
 The daily CBCT image data sets were transferred to the TPS and 





(Section 2.2c).  A bony anatomy registration was chosen for its simplicity and to 
minimize time requirements, as compared to a soft tissue registration.  The daily 
bladder and rectal contours were then copied from each daily CBCT image to the 
original planning CT image using the same bony anatomy frame of reference.  
The bladder contours included the entire volume encompassed by the bladder 
wall, including the bladder contents.  The transverse colon was the cranial 
boundary and the caudal boundary was 2 cm past the caudal end of the urinary 
bladder to include the trigone area and urethra.  The length of the rectum 
adjacent to the bladder was also contoured and included the entire rectal volume 
and its contents encompassed by the outer rectal wall.  All organ contours were 
drawn on each slice by hand by the same investigator (JRN) to ensure 
consistency.  
 A new ART treatment plan was generated based on each daily bladder 
volume for each of the four dogs.  Using CBCT allowed for improved bladder 
localization and we chose a slightly smaller PTV expansion.  A 3 mm PTV margin 
was added to each contoured bladder volume copied to the planning CT and was 
used as the new daily PTV for each new treatment (Fig. 3.3).  Again, this smaller 
PTV margin was chosen due to the increased conformality of this technique and 
the ability to better target the tumor volume.  A new 7-field IMRT plan was 
developed based on each daily target volume.  The TPS uses an iterative 
optimization to focus dose to each daily PTV and avoid each daily rectal volume.  
The treatment dose (54 Gy in 20 fractions of 2.7 Gy) was isocentrically 





the course of the treatment.  The dose distribution for each daily plan was 












FIG. 3.3  Example of daily ART treatment volumes ba sed on daily CBCT 
imaging.  Daily bladder volumes (yellow contours) b ecome the basis for 






 3.2f DVH Evaluation  
 Common dose constraints for the bladder and rectum were chosen to 
evaluate all plan types and enable the comparison of different plan types.  The 
percentage of the bladder volume receiving at least 95% of the prescribed dose 
was obtained from the DVH to evaluate bladder coverage.  This value was 
chosen based on International Commission on Radiation Units (ICRU) rules, 
common practices in the CSUVTH, and similar human studies61, 63, 65.  The 
volume of rectum, in cc, receiving at least 95% and 100% of the prescribed dose 
was obtained to evaluate rectal irradiation.  These percentages were chosen 
based on the similar human studies61. 
 
 3.2g Statistics 
 Differences in dose delivered to the bladder and rectum were compared 
between parallel opposed, bony anatomy registration, soft tissue registration, and 
ART plan types.  Results were analyzed by one-way ANOVA followed by Tukey’s 
test for individual between-group comparisons.  Statistical significance was 
assumed at P < 0.05.    
 All statistical analysis was performed using SAS statistical software v. 10.0 
(SAS, Chicago, IL, USA). 
  
3.3 Results  
 The potential improvement in dose distribution that could be gained by 





opposed plan (Section 2.3b) was evaluated.  The use of all three advanced 
planning techniques (IMRT, IGRT and ART) showed a significantly lower volume 
of the rectum receiving 100% of the prescription dose when compared to parallel 
opposed plans (p = 0.03 for IMRT, p < 0.001 for IGRT, p = 0.01 for ART).  
Similarly, the use of all three advanced planning techniques (IMRT, IGRT and 
ART) showed a significantly lower volume of the rectum receiving 95% of the 
prescription dose when compared to parallel opposed plans (p < 0.001 for IMRT, 
p = 0.005 for IGRT, p < 0.001 for ART).  ART allows for the greatest sparing of 
rectal tissue, with the lowest volume of rectum being irradiated using this 
technique (p < 0.001 for 100% and 95% of prescription dose).  ART plans also 
have the largest volume of bladder receiving 95% of the prescription dose (p < 
0.001).  All dosimetric data was obtained from the TPS-generated DVH.  Data is 
discussed in the following sections and is summarized in Table 3.1. 
 
  
3.3a Bony Anatomy Registration  
 IMRT planning using kV CBCT-based bony anatomy registration showed 
95% of the prescription dose to cover a mean bladder volume percentage ± 1 SD 
of 95.8% (range, 78.5 – 99.8%) ± 5.6% with 100% of the prescription dose being 
delivered to a mean rectal volume (cc) ± 1 SD of 3.3 ± 4.9 cc and 95% of the 







3.3b Soft Tissue Registration 
 IMRT planning using kV CBCT-based soft tissue registration showed 95% 
of the prescription dose to cover a mean bladder volume percentage ± 1 SD of 
97.3% (range, 92.0-100%) ± 2.5% with 100% of the prescription dose being 
delivered to a mean rectal volume (cc) ± 1 SD of 1.5 ± 2.2 cc and 95% of the 
prescription dose delivered to a mean rectal volume (cc) ± 1 SD of 4.4 ± 4.5 cc.  
 
 3.3c ART 
 ART IMRT planning using kV CBCT-based bony anatomy registration 
showed 95% of the prescription dose to cover a mean bladder volume 
percentage ± 1 SD of 100% (range, 100 – 100%) ± 0% with 100% of the 
prescription dose being delivered to a mean rectal volume (cc) ± 1 SD of 0.006 ± 
0.01 cc and 95% of the prescription dose delivered to a mean rectal volume (cc) 
± 1 SD of 0.4 ± 0.5 cc. 
 
  







Table 3.1 Comparison of Dose to Bladder and Rectum using Advanced RT Techniques. 







  Mean (Range) Std Dev Mean (Range) Std Dev Mean (Range) Std Dev 
Bladder – 95%
b
 95.8 (78.5-99.8) 5.6     97.3 (92.0-100.0) 2.5 100.0 (100-100) 0.0 
Rectum – 100%
c
   3.3 (0.01-20.7) 4.9 1.5 (0.0-8.3) 2.2       0.01 (0.0-0.07)   0.02 
Rectum – 95%
d
 6.7 (0.6-34.6) 7.7     4.4 (0.07-19.7) 4.5   0.4 (0.0-1.5)  0.5 
a. Advanced RT treatment technique used.  80 measurements per position (20 measurements for each of 4 dogs). 
b. Percentage of bladder volume receiving 95% of prescription dose. 
d. Rectal volume (cc) receiving 100% of prescription dose. 






3.4 Discussion of Results  
 As the field of radiation oncology progresses, new techniques become 
available to improve the outcome of RT.  Many of these have the ability to 
improve upon the standard techniques that are used for canine bladder cancer 
patients.  Image guided techniques utilizing bony or soft tissue registration, as 
well as adaptive techniques were examined.  Although none of these techniques 
are commonly used for the treatment of canine bladder cancer, results of this 
study show that all of these techniques could provide adequate bladder coverage 
while simultaneously reducing the dose received by the rectum (Figs. 3.4, 3.5).  
This dose reduction could translate to reduced treatment toxicity, in terms of both 
acute and late treatment effects and permit PTV dose escalation.  It is thought 
that the combination of IMRT and IGRT has the potential to achieve both 
unparalleled tumor control and normal tissue sparing5.   
 The treatment plans using IMRT and kV CBCT-based bony anatomy 
registration introduced a conformal technique that substantially reduced the 
amount of irradiated tissue from that which was irradiated with the parallel 
opposed plan.  One hundred percent of the prescription dose was delivered to an 
average of only 3.3 ± 4.9 cc of the total rectal volume (vs.7.0 ± 7.9 cc of the total 
rectal volume received the total dose with the parallel opposed plan).  However, 
with this dose conformality, care needs to be taken to direct the prescribed dose 
to the intended target.  There is no simple way to account for organ motion each 
day and this motion can lead to inaccurate delivery of high radiation doses.  If the 
conformal dose is not accurately delivered, geographic miss of the target or over-





 An IMRT planning technique using kV CBCT-based soft tissue registration 
was next examined.  Soft tissue registration provided an even more 
advantageous dose distribution with the rectal volume receiving 100% of the 
prescribed dose of 1.5 ± 2.2 cc.  This could be particularly advantageous during 
RT for bladder cancer with respect to the close proximity of the bladder and 
rectum.  The highly conformal doses that are used with IMRT need to be 
delivered to the appropriate location each day or the treatment outcome will be 
compromised.  
 The possibility of adapting the daily plan based on the CBCT images was 
examined.  We accomplished this by using IMRT planning techniques that 
utilized kV CBCT-based bony anatomy registration.  This type of ART planning 
showed the best dose distribution of all the plans we examined (p < 0.001), with 
100% of each daily bladder volume receiving the full 54 Gy prescription dose and 
only 0.006 ± 0.01 cc of the total rectal volume receiving the entire prescribed 
dose.  This type of adaptation requires a new plan to be made each day, so the 
practicality of using this type of RT in a clinical setting would need to be 
examined. 
 Possible downfalls to these types of image guided therapy would be the 
need for images of high-enough quality to easily visualize the entire bladder 
volume each day.  This type of technology is not yet available to all facilities but it 
is growing.  Another possible obstacle would be the need to train and familiarize 
radiation therapists with the soft tissue registration technique as the advanced 





veterinary facilities.  Another consideration is the added dose from the daily 
CBCT imaging.  The estimated dose of each CBCT is approximately 2-3 cGy45, 
which would therefore add less than 1 Gy to the total treatment dose. However, 
this cannot be directly compared with a large treatment dose of 54 Gy because 
the treatment dose is conformed to the target volume only, while the CBCT dose 
includes the entire imaged volume.  In addition, the imaging dose is in the kV 
range, while the treatment dose in the higher MV range.  The risk of a second 

















FIG. 3.4  Graph of average bladder volume (%) recei ving at least 95% of 54 























































FIG. 3.5  Graph of average rectal volume (cc) recei ving 95% (orange) and 









































CHAPTER 4  
GENERAL DISCUSSION and CONCLUSION 
 
4.1 Summary and Discussion of Results 
 The nature of this study and the CBCT imaging technology allowed for the 
examination of the actual daily variations in position and treatment dose 
experienced by the canine bladder and allowed for the examination of different 
treatment scenarios using retrospective patient data.  Characterization of the 
type of variation experienced by the canine bladder, determination of which 
treatment position provides the best dose distribution, and examination of the 
dose distributions resulting from three PTV expansions using a routine parallel-
opposed treatment plan was performed.  This information then allowed an 
evaluation of using more advanced RT treatment techniques for the treatment of 
canine bladder cancer.  Sample plans were based on retrospective patient 
imaging data and provided insight into the possibility of using these types of 
techniques in a clinical setting. 
 There has been an increase in use of radiation oncology in veterinary 
medical practice over the past decade1 with 69 clinics currently offering some 
form of external radiation therapy4, ranging from linear accelerators to 
orthovoltage.  However, treatment technologies and protocols differ from facility 





decisions based on actual patient data that will enable them to optimize 
treatment with the modalities available to them 
 
4.2 Future Directions 
 4.2a Clinical Application of ART 
 The ability to assess positional differences on a daily basis and adapt the 
plan based on these variations enables more conformal treatment strategies to 
be implemented.  Other than resource implications and imaging dose (Section 
3.4), the only disadvantage to using such ART technology in a clinical setting is 
the time constraints.  For each new ART plan created each day, the CBCT has to 
be transferred to the TPS and new contours have to be drawn by hand for the 
key organ(s) of interest, as well as a new PTV structure.  A new IMRT plan has 
to be constructed that uses the new bladder volume PTV as an objective and this 
new plan has to be optimized.  The dose would then have to be calculated and 
approved before it could be sent back to the treatment delivery machine and 
delivered to the patient.   
 An estimated minimum of 40 minutes would be needed to complete ART 
plans for each individual day of a treatment based on construction of our sample 
ART plans (Table 4.1).  Additional planning time will add up in a busy clinic, 
increasing both clinical personnel time and canine patient time under anesthesia.  
The possibility for anesthesia-related complications will increase and may also 





hybrid form of plan adaptation could be utilized to combat these time-related 













Table 4.1  Estimated Time to Complete ART and Hybri d ART Planning 
  ART Hybrid ART  
CBCT 5 min/day 5 min/day 
Registration Type Bony Anatomy Soft Tissue 
Registration  5 min/day 5 min/day 
Contouring 10 min/day N/A 
Planning 10 min/day 2 min/day 
Optimization 10 min/day N/A 






 4.2b Hybrid ART Plan 
 A hybrid planning technique was proposed that combined image guidance 
with a choice of pre-calculated plans to achieve the benefit of ART but without 
the time constraints.  This type of planning technique may provide the tumor 
targeting and normal tissue sparing that is seen with ART.  A hybrid approach 
eliminates the need to re-contour the bladder and rectal volumes each day and 
would therefore reduce the amount of time needed to develop an adaptive plan. 
 Hybrid ART utilizes pre-treatment CBCT to evaluate the patient position 
and bladder motion characteristics each day, immediately prior to treatment.  The 
radiation therapist would then chose a plan from a library of plans that best fits 
that day’s bladder volume.  A soft tissue registration would be performed and the 
dose for the best-fitting plan would be delivered. 
 The bladder characterization data from Aim 1 of this study was used to 
develop the hybrid ART plans.  Again, similar to the daily ART plans, only dogs in 
lateral recumbency were examined, as this was found to be the treatment 
position with the least interfractional variation.  The feasibility of this technique 
was tested using a small (Fig. 4.1), medium (Fig. 4.2) and large plan (Fig. 4.3).  
Since bladder wall motion is most pronounced in the cranial and ventral 
directions, non-uniform margins were used to construct the target volumes for 
each of the plans (Table 4.2).  The small plan applied a 5 mm PTV expansion in 
each of these directions to the original bladder volume, but did not add a margin 
in any of the other directions.  This does not imply that there is no bladder wall 





other bladder walls fits within the original planning CT bladder volume.  The 
medium plan applied a 15 mm expansion to the ventral wall, a 5 mm expansion 
to the cranial wall and a 3 mm expansion to the right, left, caudal and dorsal walls 
of the planning CT bladder volume.  The large plan applied a 20 mm expansion 
to the ventral wall, a 10 mm expansion to the cranial wall, a 5 mm expansion to 
the right and left walls and a 3 mm expansion to the dorsal and caudal walls. 
 A 7-field IMRT plan using kV CBCT-based soft tissue registration was 
developed to deliver 54 Gy in 20 fractions of 2.7 Gy.  We examined the DVH for 
each day using the same criteria as we did for the previous plans.  This sample 
case of a hybrid ART plan provided a favorable dose distribution that fell between  
than that seen for IGRT with soft tissue registrations and ART.  Our example 
hybrid ART plan using a soft tissue registration showed 95% of the prescription 
dose to cover a mean bladder volume percentage ± 1 SD of 97.6% (range, 
94.0% – 99.9%) ± 1.7% with 100% of the prescription dose being delivered to a 
mean rectal volume (cc) ± 1 SD of 0.2 ± 0.4 cc and 95% of the prescription dose 
delivered to a mean rectal volume (cc) ± 1 SD of 1.2 ± 1.6 cc.  The Hybrid RT 
plan is seen compared with the four other plan types in Figures 4.4 and 4.5. 
 Based on this data, it is feasible that a practical, hybrid ART technique 
utilizing CBCT-assisted plan selection could be developed to reduce the volume 
of rectum receiving high doses and continue to provide adequate coverage to the 
bladder volume.  A hybrid ART technique would provide plan adaptation based 
on the patient anatomy each day, but it would reduce the time required to re-plan 
















FIG. 4.1  Small, medium and large PTV volumes (gree n) shown on planning 
CT image with bladder volume (yellow) from one dail y CBCT.  The bladder 
volume fits within the small PTV (think green conto ur), so the small plan 

















FIG. 4.2  Small, medium and large PTV volumes (gree n) shown on planning 
CT image with bladder volume (yellow) from one dail y CBCT.  The bladder 
volume fits within the medium PTV (think green cont our), so the medium 

















FIG. 4.3  Small, medium and large PTV volumes (gree n) shown on planning 
CT image with bladder volume (yellow) from one dail y CBCT.  The bladder 
volume fits within the large PTV (think green conto ur), so the large plan 


















Table 4.2  Hybrid ART Margins (mm) Applied to Origi nal Planning CT    
 Bladder Volume in each Direction 
 
  Small  Medium  Large  
Right 0 3 5 
Left 0 3 5 
Dorsal 0 3 3 
Ventral 5 15 2 
Cranial 5 5 1 


















FIG 4.4  Graph of average bladder volume (%) receiv ing at least 95% of 54 



























































FIG. 4.5  Graph of average rectal volume (cc) recei ving at least 95% 
(orange) and at least 100% (red) of 54 Gy prescribe d dose for each plan 









































4.2c Proposed Clinical Trial   
 This study shows that volumetric information obtained from CBCT image 
data during the treatment of canine bladder cancer could be used to reduce the 
dose to critical organs, such as the colon and rectum.  Many different planning 
techniques are feasible for the treatment of bladder cancer based on this 
retrospective data.  Evaluation of these techniques in a clinical setting is needed 
to determine practicality and efficacy, and to create an optimal protocol for canine 
bladder cancer with more optimistic outcomes for patients. 
 
4.3 Translational Medicine  
 Valid animal models are needed to test new cancer therapies.  Animal 
models facilitate a better understanding of the molecular and biological 
processes involved in the tumor response, as well as provide information about 
treatment delivery and side effects.  With more than 50,000 people diagnosed 
with bladder cancer each year in the United States66, animal models could be 
helpful in developing a more effective treatment for this malignancy. 
 Canine TCC has been found to be similar to human TCC with regards to 
histopathology, biological behavior, metastasis, response to therapy, and 
prognosis28 (Table 4.3).  Pet dogs share the same environment as their owners, 
with exposure to the same water, air and chemicals.  These similarities could 
make dogs a very effective model for human bladder TCC.  Dogs are also of a 
larger size than most laboratory rodents and this makes testing of clinical 











Table 4.3  Human and Canine TCC Similarities 28 
  Canine TCC  Human TCC  
% of all cancers 1.5-2% 2% 
mean age at diagnosis 11 yrs (60 human 
equiv. yrs) 
65 yrs 
environmental risk increased risk in urban 
areas; increased risk 
with benzene exposure 
increased risk in urban 
areas; increased risk 
with benzene exposure 
histopathology invasive; intermed. to 
high grade 
invasive; intermed. to 
high grade 
metastasis at diagnosis 20% of dogs 5-20% of patients 
sites of metastasis regional nodes and 
lung most common 
regional nodes and 
lung most common 








Not only do studies performed on dogs benefit humans, but 
advancements in human medicine can be used to improve the treatment of 
similar malignancies in veterinary patients.  Information from human bladder 
cancer studies, combined with information from this study, could improve the 
treatment outcome for canine bladder TCC.  Human studies have shown that 
higher total doses, up to 84 Gy, produce the best long term tumor control and 
survival rates67.  Evidence that increasing the dose above current human 
standards (60–64 Gy with conventional fractionation) leads to improved local 
tumor control for bladder cancer has also been found in other clinical studies67, 68.   
 Most late effects were documented in these human studies at total doses 
higher than 45-60 Gy.  Dose escalation above current veterinary treatment 
standards may be a possible method to achieve better local tumor control for 
canine patients.  However, to avoid overirradiation of the rectum and unwanted 
side effects, highly conformal doses need to be delivered using image guidance 
and appropriate PTV margins.  The results and techniques examined in this 
study could be instrumental in optimizing bladder cancer treatment protocols. 
 
4.4 Conclusions 
 Prior to this study, little information was available that characterized or 
quantified the motion experienced by the canine bladder on a daily basis, 
throughout the course of fractionated RT.  The results of this study have allowed 





recommend the treatment set-up that will minimize these variations.  This study 
has also allowed us to examine the effects these interfractional bladder variations 
would have on model dose distributions for different treatment planning 
techniques. 
 
 4.4a Characterization of Bladder Variations 
 Aim 1 of this study used CBCT imaging technology to: 
 
1. quantify the daily motion characteristics of the canine urinary bladder in 
three different treatment positions,  and 
2. recommend a PTV expansion margin that would ensure adequate 
irradiation of the entire bladder each day, while minimizing irradiation 
of the rectum, leading to unacceptable complications. 
 
 Quantification of the daily bladder wall position variations experienced by 
the canine urinary bladder on a daily basis with dogs in three possible treatment 
positions was done by making distance measurements in six directions.  These 
data were then used to determine that dogs in lateral recumbency showed the 
least amount of bladder wall variation, and therefore the most advantageous 
treatment position.   
 In addition to taking bladder variation measurements, a 5, 10 or 15 mm 
treatment margin was added to the planning CT bladder volume.   Sample 





examined.  The recommended 10 mm PTV expansion ensured adequate 
irradiation of the entire bladder each day while minimizing the dose received by 
the rectum. 
 
 4.4b Optimization of Bladder Cancer Radiation Thera py using  
  Motion Data 
 Aim 2 of this study used the bladder motion data from Aim 1 to: 
 
1. develop plans and compare dosimetric data for different advanced RT 
techniques, and 
2. develop an adaptive RT (ART) protocol that would optimize the dose 
delivery for canine bladder cancer. 
  
 The bladder motion and treatment setup data from Aim 1 was used to 
create different types of advanced RT plans.  Advanced plan types evaluated 
included an intensity modulated RT (IMRT) plan using bony anatomy registration 
and an IMRT plan using soft tissue registration. The feasibility of an ART plan 
that used a new target volume based on each day’s anatomy was also 
examined.  The dosimetric data for the new plans, as well as the dosimetric data 
from the parallel opposed plans in Aim 1, was compared using DVH’s and all 
advanced planning techniques showed a lower dose to the rectal volume.  The 





conformal, curative-intent dose to the bladder while simultaneously providing the 
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LIST OF ABBREVIATIONS 
 
 
ANOVA Analysis of Variance 
ART Adaptive Radiotherapy 
CBCT Cone Beam Computed Tomography 
cc Cubic Centimeters 
CRT Conformal Radiation Therapy 
CSU Colorado State University 
CSUVTH Colorado State University Veterinary Teaching 
Hospital 
CT Computed Tomography 
CTV Clinical Target Volume 
DART Dynamic Adaptive Radiotherapy 
DVH Dose Volume Histogram 
GTV Gross Target Volume 
Gy Gray 
IGRT Image Guided Radiotherapy 
IMRT Intenisty Modulated Radiotherapy 
kV Kiolovoltage 
mA Miliamps 
MeV Mega Electronvolts 
mm Millimeter 
MV Megavoltage 
NSAID Non-steroidal Anti-inflammatory Drugs 
PTV Planning Target Volume 
RT Radiotherapy/Radiation Therapy 
SD Standard Deviation 
TCC Transitional Cell Carcinoma 






SAS STATISTICAL ANALYSIS OUTPUT 
 
Dependent variable = Rt                                           13:54 
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The Mixed Procedure 
 
                  Model Information 
 
Data Set                     WORK.TEMP 
Dependent Variable           Rt 
Covariance Structure         Variance Components 
Estimation Method            REML 
Residual Variance Method     Profile 
Fixed Effects SE Method      Model-Based 
Degrees of Freedom Method    Containment 
 
 
              Class Level Information 
 
Class       Levels    Values 
 
Position         3    1 2 3 
Dog             10    1 2 3 4 5 6 7 8 9 10 
 
 
            Dimensions 
 
Covariance Parameters             2 
Columns in X                      4 
Columns in Z                     10 
Subjects                          1 
Max Obs Per Subject             111 
 
 
          Number of Observations 
 
Number of Observations Read             111 
Number of Observations Used             111 
Number of Observations Not Used           0 
 
 
                     Iteration History 
 
Iteration    Evaluations    -2 Res Log Like       Criterion 
 
        0              1       -34.83949419 






        2              1       -37.13693930      0.00024404 
        3              1       -37.16892209      0.00000922 
4              1       -37.17003714      0.00000001 
        5              1       -37.17003889      0.00000000 
 
 
                   Convergence criteria met.
 
Dependent variable = Rt                                           13:54 
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The Mixed Procedure 
 
Covariance Parameter 
      Estimates 
 
Cov Parm     Estimate 
 
Dog          0.007822 
Residual      0.03495 
 
 
           Fit Statistics 
 
-2 Res Log Likelihood           -37.2 
AIC (smaller is better)         -33.2 
AICC (smaller is better)        -33.1 
BIC (smaller is better)         -32.6 
 
 
        Type 3 Tests of Fixed Effects 
 
              Num     Den 
Effect         DF      DF    F Value    Pr > F 
 
Position        2     101       3.16    0.0465 
 
 
                            Least Squares Means 
 
                                    Standard 
Effect      Position    Estimate       Error      DF    t Value    Pr > 
|t| 
 
Position    1             1.0024     0.05828     101      17.20      
<.0001 
Position    2             0.9026     0.05790     101      15.59      
<.0001 




                          Differences of Least Squares Means 
 





Effect      Position    Position    Estimate       Error      DF    t 
Value    Pr > |t| 
 
Position    1           2            0.09976     0.08215     101       
1.21      0.2274 
Position    1           3             0.2166     0.08612     101       
2.51      0.0135 
Position    2           3             0.1168     0.08587     101       
1.36      0.1767 
Dependent variable = Lt                                           13:54 
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The Mixed Procedure 
 
                  Model Information 
 
Data Set                     WORK.TEMP 
Dependent Variable           Lt 
Covariance Structure         Variance Components 
Estimation Method            REML 
Residual Variance Method     Profile 
Fixed Effects SE Method      Model-Based 
Degrees of Freedom Method    Containment 
 
 
              Class Level Information 
 
Class       Levels    Values 
 
Position         3    1 2 3 
Dog             10    1 2 3 4 5 6 7 8 9 10 
 
 
            Dimensions 
 
Covariance Parameters             2 
Columns in X                      4 
Columns in Z                     10 
Subjects                          1 
Max Obs Per Subject             111 
 
 
          Number of Observations 
 
Number of Observations Read             111 
Number of Observations Used             111 
Number of Observations Not Used           0 
 
 
                     Iteration History 
 
Iteration    Evaluations    -2 Res Log Like       Criterion 
 
        0              1         0.02882730 
        1              2       -15.61009005      0.00000093 







                   Convergence criteria met. 
 
 
Dependent variable = Lt                                           13:54 
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The Mixed Procedure 
 
Covariance Parameter 
      Estimates 
 
Cov Parm     Estimate 
 
Dog           0.01771 
Residual      0.04143 
 
 
           Fit Statistics 
 
-2 Res Log Likelihood           -15.6 
AIC (smaller is better)         -11.6 
AICC (smaller is better)        -11.5 
BIC (smaller is better)         -11.0 
 
 
        Type 3 Tests of Fixed Effects 
 
              Num     Den 
Effect         DF      DF    F Value    Pr > F 
 
Position        2     101       0.41    0.6644 
 
 
                            Least Squares Means 
 
                                    Standard 
Effect      Position    Estimate       Error      DF    t Value    Pr > 
|t| 
 
Position    1             0.8703     0.08271     101      10.52      
<.0001 
Position    2             0.9511     0.07912     101      12.02      
<.0001 




                          Differences of Least Squares Means 
 
                                                Standard 
Effect      Position    Position    Estimate       Error      DF    t 
Value    Pr > |t| 
 
Position    1           2           -0.08085      0.1145     101      -





Position    1           3            -0.1015      0.1204     101      -
0.84      0.4010 
Position    2           3           -0.02067      0.1179     101      -
0.18      0.8612 
Dependent variable = Dor                                          13:54 
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The Mixed Procedure 
 
                  Model Information 
 
Data Set                     WORK.TEMP 
Dependent Variable           Dor 
Covariance Structure         Variance Components 
Estimation Method            REML 
Residual Variance Method     Profile 
Fixed Effects SE Method      Model-Based 
Degrees of Freedom Method    Containment 
 
 
              Class Level Information 
 
Class       Levels    Values 
 
Position         3    1 2 3 
Dog             10    1 2 3 4 5 6 7 8 9 10 
 
 
            Dimensions 
 
Covariance Parameters             2 
Columns in X                      4 
Columns in Z                     10 
Subjects                          1 
Max Obs Per Subject             111 
 
 
          Number of Observations 
 
Number of Observations Read             111 
Number of Observations Used             111 
Number of Observations Not Used           0 
 
 
                     Iteration History 
 
Iteration    Evaluations    -2 Res Log Like       Criterion 
 
        0              1        15.44848144 
        1              3        -5.96124296      0.00035421 
        2              1        -6.00134708      0.00001223 
        3              1        -6.00262787      0.00000002 
        4              1        -6.00262964      0.00000000 
 
 





Dependent variable = Dor                                          13:54 
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The Mixed Procedure 
 
Covariance Parameter 
      Estimates 
 
Cov Parm     Estimate 
 
Dog           0.02143 
Residual      0.04505 
 
 
           Fit Statistics 
 
-2 Res Log Likelihood            -6.0 
AIC (smaller is better)          -2.0 
AICC (smaller is better)         -1.9 
BIC (smaller is better)          -1.4 
 
 
        Type 3 Tests of Fixed Effects 
 
              Num     Den 
Effect         DF      DF    F Value    Pr > F 
 
Position        2     101       0.96    0.3875 
 
 
                            Least Squares Means 
 
                                    Standard 
Effect      Position    Estimate       Error      DF    t Value    Pr > 
|t| 
 
Position    1             1.0497     0.09034     101      11.62      
<.0001 
Position    2             1.0874     0.08590     101      12.66      
<.0001 




                          Differences of Least Squares Means 
 
                                                Standard 
Effect      Position    Position    Estimate       Error      DF    t 
Value    Pr > |t| 
 
Position    1           2           -0.03763      0.1247     101      -
0.30      0.7634 
Position    1           3             0.1337      0.1312     101       
1.02      0.3104 
Position    2           3             0.1714      0.1282     101       





Dependent variable = Ven                                          13:54 
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The Mixed Procedure 
 
                  Model Information 
 
Data Set                     WORK.TEMP 
Dependent Variable           Ven 
Covariance Structure         Variance Components 
Estimation Method            REML 
Residual Variance Method     Profile 
Fixed Effects SE Method      Model-Based 
Degrees of Freedom Method    Containment 
 
 
              Class Level Information 
 
Class       Levels    Values 
 
Position         3    1 2 3 
Dog             10    1 2 3 4 5 6 7 8 9 10 
 
 
            Dimensions 
 
Covariance Parameters             2 
Columns in X                      4 
Columns in Z                     10 
Subjects                          1 
Max Obs Per Subject             111 
 
 
          Number of Observations 
 
Number of Observations Read             111 
Number of Observations Used             111 
Number of Observations Not Used           0 
 
 
                     Iteration History 
 
Iteration    Evaluations    -2 Res Log Like       Criterion 
 
        0              1        47.31118084 
        1              5         7.00383917      0.00011255 
        2              1         6.99400249      0.00000158 
        3              1         6.99385032      0.00000000 
 
 
                   Convergence criteria met. 
 
 
Dependent variable = Ven                                          13:54 
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      Estimates 
 
Cov Parm     Estimate 
 
Dog           0.04318 
Residual      0.04917 
 
 
           Fit Statistics 
 
-2 Res Log Likelihood             7.0 
AIC (smaller is better)          11.0 
AICC (smaller is better)         11.1 
BIC (smaller is better)          11.6 
 
 
        Type 3 Tests of Fixed Effects 
 
              Num     Den 
Effect         DF      DF    F Value    Pr > F 
 
Position        2     101       1.86    0.1617 
 
 
                            Least Squares Means 
 
                                    Standard 
Effect      Position    Estimate       Error      DF    t Value    Pr > 
|t| 
 
Position    1             0.7867      0.1245     101       6.32      
<.0001 
Position    2             0.6788      0.1148     101       5.91      
<.0001 




                          Differences of Least Squares Means 
 
                                                Standard 
Effect      Position    Position    Estimate       Error      DF    t 
Value    Pr > |t| 
 
Position    1           2             0.1080      0.1693     101       
0.64      0.5252 
Position    1           3            -0.2212      0.1790     101      -
1.24      0.2194 
Position    2           3            -0.3292      0.1724     101      -
1.91      0.0590 
Dependent variable = Cra                                          13:54 
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                  Model Information 
 
Data Set                     WORK.TEMP 
Dependent Variable           Cra 
Covariance Structure         Variance Components 
Estimation Method            REML 
Residual Variance Method     Profile 
Fixed Effects SE Method      Model-Based 
Degrees of Freedom Method    Containment 
 
 
              Class Level Information 
 
Class       Levels    Values 
 
Position         3    1 2 3 
Dog             10    1 2 3 4 5 6 7 8 9 10 
 
 
            Dimensions 
 
Covariance Parameters             2 
Columns in X                      4 
Columns in Z                     10 
Subjects                          1 
Max Obs Per Subject             111 
 
 
          Number of Observations 
 
Number of Observations Read             111 
Number of Observations Used             111 
Number of Observations Not Used           0 
 
 
                     Iteration History 
 
Iteration    Evaluations    -2 Res Log Like       Criterion 
 
        0              1       179.52788948 
        1              3       126.55791552      0.00103777 
        2              1       126.51656860      0.00003597 
        3              1       126.51524259      0.00000005 
        4              1       126.51524073      0.00000000 
 
 
                   Convergence criteria met. 
Dependent variable = Cra                                          13:54 
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The Mixed Procedure 
 
Covariance Parameter 
      Estimates 
 






Dog            0.1873 
Residual       0.1455 
 
 
           Fit Statistics 
 
-2 Res Log Likelihood           126.5 
AIC (smaller is better)         130.5 
AICC (smaller is better)        130.6 
BIC (smaller is better)         131.1 
 
 
        Type 3 Tests of Fixed Effects 
 
              Num     Den 
Effect         DF      DF    F Value    Pr > F 
 
Position        2     101       1.47    0.2345 
 
 
                            Least Squares Means 
 
                                    Standard 
Effect      Position    Estimate       Error      DF    t Value    Pr > 
|t| 
 
Position    1             0.6386      0.2564     101       2.49      
0.0144 
Position    2             1.2229      0.2326     101       5.26      
<.0001 




                          Differences of Least Squares Means 
 
                                                Standard 
Effect      Position    Position    Estimate       Error      DF    t 
Value    Pr > |t| 
 
Position    1           2            -0.5843      0.3462     101      -
1.69      0.0945 
Position    1           3            -0.2243      0.3669     101      -
0.61      0.5423 
Position    2           3             0.3599      0.3507     101       
1.03      0.3071 
 
 
Dependent variable = Cau                                          13:54 
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The Mixed Procedure 
 
                  Model Information 
 
Data Set                     WORK.TEMP 





Covariance Structure         Variance Components 
Estimation Method            REML 
Residual Variance Method     Profile 
Fixed Effects SE Method      Model-Based 
Degrees of Freedom Method    Containment 
 
 
              Class Level Information 
 
Class       Levels    Values 
 
Position         3    1 2 3 
Dog             10    1 2 3 4 5 6 7 8 9 10 
 
 
            Dimensions 
 
Covariance Parameters             2 
Columns in X                      4 
Columns in Z                     10 
Subjects                          1 
Max Obs Per Subject             111 
 
 
          Number of Observations 
 
Number of Observations Read             111 
Number of Observations Used             111 
Number of Observations Not Used           0 
 
 
                     Iteration History 
 
Iteration    Evaluations    -2 Res Log Like       Criterion 
 
        0              1      -111.86993398 
        1              3      -120.51007284      0.00086303 
        2              1      -120.67170972      0.00009492 
        3              1      -120.68802161      0.00000154 
        4              1      -120.68826953      0.00000000 
 
 
                   Convergence criteria met. 
Dependent variable = Cau                                          13:54 
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The Mixed Procedure 
 
Covariance Parameter 
      Estimates 
 
Cov Parm     Estimate 
 
Dog          0.003510 







           Fit Statistics 
 
-2 Res Log Likelihood          -120.7 
AIC (smaller is better)        -116.7 
AICC (smaller is better)       -116.6 
BIC (smaller is better)        -116.1 
 
 
        Type 3 Tests of Fixed Effects 
 
              Num     Den 
Effect         DF      DF    F Value    Pr > F 
 
Position        2     101       5.54    0.0052 
 
 
                            Least Squares Means 
 
                                    Standard 
Effect      Position    Estimate       Error      DF    t Value    Pr > 
|t| 
 
Position    1             0.9914     0.03917     101      25.31      
<.0001 
Position    2             0.9253     0.03898     101      23.74      
<.0001 




                          Differences of Least Squares Means 
 
                                                Standard 
Effect      Position    Position    Estimate       Error      DF    t 
Value    Pr > |t| 
 
Position    1           2            0.06611     0.05526     101       
1.20      0.2344 
Position    1           3             0.1912     0.05793     101       
3.30      0.0013 
Position    2           3             0.1251     0.05780     101       
2.16      0.0328 
Dependent variable = __5B95                                       13:54 
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The Mixed Procedure 
 
                  Model Information 
 
Data Set                     WORK.TEMP 
Dependent Variable           __5B95 
Covariance Structure         Variance Components 
Estimation Method            REML 
Residual Variance Method     Profile 
Fixed Effects SE Method      Model-Based 







              Class Level Information 
 
Class       Levels    Values 
 
Position         3    1 2 3 
Dog             10    1 2 3 4 5 6 7 8 9 10 
 
 
            Dimensions 
 
Covariance Parameters             2 
Columns in X                      4 
Columns in Z                     10 
Subjects                          1 
Max Obs Per Subject             111 
 
 
          Number of Observations 
 
Number of Observations Read             111 
Number of Observations Used             111 
Number of Observations Not Used           0 
 
 
                     Iteration History 
 
Iteration    Evaluations    -2 Res Log Like       Criterion 
 
        0              1       713.57984224 
        1              2       697.42979502      0.00000199 
        2              1       697.42929167      0.00000000 
 
 
                   Convergence criteria met. 
 
 
Dependent variable = __5B95                                       13:54 
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The Mixed Procedure 
 
Covariance Parameter 
      Estimates 
 
Cov Parm     Estimate 
 
Dog           13.7638 
Residual      30.4400 
 
 
           Fit Statistics 
 
-2 Res Log Likelihood           697.4 
AIC (smaller is better)         701.4 
AICC (smaller is better)        701.5 







        Type 3 Tests of Fixed Effects 
 
              Num     Den 
Effect         DF      DF    F Value    Pr > F 
 
Position        2     101       2.50    0.0869 
 
 
                            Least Squares Means 
 
                                    Standard 
Effect      Position    Estimate       Error      DF    t Value    Pr > 
|t| 
 
Position    1            91.1067      2.2969     101      39.66      
<.0001 
Position    2            98.1543      2.1903     101      44.81      
<.0001 




                          Differences of Least Squares Means 
 
                                                Standard 
Effect      Position    Position    Estimate       Error      DF    t 
Value    Pr > |t| 
 
Position    1           2            -7.0476      3.1739     101      -
2.22      0.0286 
Position    1           3            -4.4824      3.3392     101      -
1.34      0.1825 
Position    2           3             2.5652      3.2668     101       
0.79      0.4342 
Dependent variable = __5R100                                      13:54 
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The Mixed Procedure 
 
                  Model Information 
 
Data Set                     WORK.TEMP 
Dependent Variable           __5R100 
Covariance Structure         Variance Components 
Estimation Method            REML 
Residual Variance Method     Profile 
Fixed Effects SE Method      Model-Based 
Degrees of Freedom Method    Containment 
 
 
              Class Level Information 
 
Class       Levels    Values 
 





Dog             10    1 2 3 4 5 6 7 8 9 10 
 
 
            Dimensions 
 
Covariance Parameters             2 
Columns in X                      4 
Columns in Z                     10 
Subjects                          1 
Max Obs Per Subject             111 
 
 
          Number of Observations 
 
Number of Observations Read             111 
Number of Observations Used             111 
Number of Observations Not Used           0 
 
 
                     Iteration History 
 
Iteration    Evaluations    -2 Res Log Like       Criterion 
 
        0              1       799.52569595 
        1              3       770.15960185      0.00032319 
        2              1       770.05332561      0.00002472 
        3              1       770.04587885      0.00000019 
        4              1       770.04582529      0.00000000 
 
 
                   Convergence criteria met. 
Dependent variable = __5R100                                      13:54 
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The Mixed Procedure 
 
Covariance Parameter 
      Estimates 
 
Cov Parm     Estimate 
 
Dog           37.7227 
Residual      58.5455 
 
 
           Fit Statistics 
 
-2 Res Log Likelihood           770.0 
AIC (smaller is better)         774.0 
AICC (smaller is better)        774.2 
BIC (smaller is better)         774.7 
 
 
        Type 3 Tests of Fixed Effects 
 
              Num     Den 






Position        2     101       0.84    0.4338 
 
 
                            Least Squares Means 
 
                                    Standard 
Effect      Position    Estimate       Error      DF    t Value    Pr > 
|t| 
 
Position    1            10.9865      3.7281     101       2.95      
0.0040 
Position    2            12.2353      3.4876     101       3.51      
0.0007 




                          Differences of Least Squares Means 
 
                                                Standard 
Effect      Position    Position    Estimate       Error      DF    t 
Value    Pr > |t| 
 
Position    1           2            -1.2488      5.1051     101      -
0.24      0.8072 
Position    1           3             5.2549      5.3844     101       
0.98      0.3314 
Position    2           3             6.5037      5.2208     101       
1.25      0.2157 
Dependent variable = __0B95                                       13:54 
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The Mixed Procedure 
 
                  Model Information 
 
Data Set                     WORK.TEMP 
Dependent Variable           __0B95 
Covariance Structure         Variance Components 
Estimation Method            REML 
Residual Variance Method     Profile 
Fixed Effects SE Method      Model-Based 
Degrees of Freedom Method    Containment 
 
 
              Class Level Information 
 
Class       Levels    Values 
 
Position         3    1 2 3 
Dog             10    1 2 3 4 5 6 7 8 9 10 
 
 
            Dimensions 
 





Columns in X                      4 
Columns in Z                     10 
Subjects                          1 
Max Obs Per Subject             111 
 
 
          Number of Observations 
 
Number of Observations Read             111 
Number of Observations Used             111 
Number of Observations Not Used           0 
 
 
                     Iteration History 
 
Iteration    Evaluations    -2 Res Log Like       Criterion 
 
        0              1       632.56388697 
        1              3       617.24617895      0.00011082 
        2              1       617.22086920      0.00000260 
        3              1       617.22031595      0.00000000 
 
 
                   Convergence criteria met. 
 
 
Dependent variable = __0B95                                       13:54 
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The Mixed Procedure 
 
Covariance Parameter 
      Estimates 
 
Cov Parm     Estimate 
 
Dog            5.3078 
Residual      14.6416 
 
 
           Fit Statistics 
 
-2 Res Log Likelihood           617.2 
AIC (smaller is better)         621.2 
AICC (smaller is better)        621.3 
BIC (smaller is better)         621.8 
 
 
        Type 3 Tests of Fixed Effects 
 
              Num     Den 
Effect         DF      DF    F Value    Pr > F 
 
Position        2     101       1.67    0.1929 
 
 






                                    Standard 
Effect      Position    Estimate       Error      DF    t Value    Pr > 
|t| 
 
Position    1            95.3936      1.4492     101      65.83      
<.0001 
Position    2            98.9909      1.3996     101      70.73      
<.0001 




                          Differences of Least Squares Means 
 
                                                Standard 
Effect      Position    Position    Estimate       Error      DF    t 
Value    Pr > |t| 
 
Position    1           2            -3.5972      2.0147     101      -
1.79      0.0772 
Position    1           3            -2.5908      2.1167     101      -
1.22      0.2238 
Position    2           3             1.0064      2.0830     101       
0.48      0.6300 
 
 
Dependent variable = __0R100                                      13:54 
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The Mixed Procedure 
 
                  Model Information 
 
Data Set                     WORK.TEMP 
Dependent Variable           __0R100 
Covariance Structure         Variance Components 
Estimation Method            REML 
Residual Variance Method     Profile 
Fixed Effects SE Method      Model-Based 
Degrees of Freedom Method    Containment 
 
 
              Class Level Information 
 
Class       Levels    Values 
 
Position         3    1 2 3 
Dog             10    1 2 3 4 5 6 7 8 9 10 
 
 
            Dimensions 
 
Covariance Parameters             2 
Columns in X                      4 
Columns in Z                     10 





Max Obs Per Subject             111 
 
 
          Number of Observations 
 
Number of Observations Read             111 
Number of Observations Used             111 
Number of Observations Not Used           0 
 
 
                     Iteration History 
 
Iteration    Evaluations    -2 Res Log Like       Criterion 
 
        0              1       829.65339723 
        1              3       810.21903034      0.00004641 
        2              1       810.20379669      0.00000067 
        3              1       810.20358820      0.00000000 
 
 
                   Convergence criteria met. 
 
 
Dependent variable = __0R100                                      13:54 
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The Mixed Procedure 
 
Covariance Parameter 
      Estimates 
 
Cov Parm     Estimate 
 
Dog           38.4526 
Residual      86.5609 
 
 
           Fit Statistics 
 
-2 Res Log Likelihood           810.2 
AIC (smaller is better)         814.2 
AICC (smaller is better)        814.3 
BIC (smaller is better)         814.8 
 
 
        Type 3 Tests of Fixed Effects 
 
              Num     Den 
Effect         DF      DF    F Value    Pr > F 
 
Position        2     101       0.43    0.6513 
 
 
                            Least Squares Means 
 





Effect      Position    Estimate       Error      DF    t Value    Pr > 
|t| 
 
Position    1            14.2525      3.8437     101       3.71      
0.0003 
Position    2            17.5986      3.6690     101       4.80      
<.0001 




                          Differences of Least Squares Means 
 
                                                Standard 
Effect      Position    Position    Estimate       Error      DF    t 
Value    Pr > |t| 
 
Position    1           2            -3.3461      5.3137     101      -
0.63      0.5303 
Position    1           3             1.5550      5.5899     101       
0.28      0.7814 
Position    2           3             4.9012      5.4712     101       
0.90      0.3725 
Dependent variable = __5B950                                      13:54 
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The Mixed Procedure 
 
                  Model Information 
 
Data Set                     WORK.TEMP 
Dependent Variable           __5B950 
Covariance Structure         Variance Components 
Estimation Method            REML 
Residual Variance Method     Profile 
Fixed Effects SE Method      Model-Based 
Degrees of Freedom Method    Containment 
 
 
              Class Level Information 
 
Class       Levels    Values 
 
Position         3    1 2 3 
Dog             10    1 2 3 4 5 6 7 8 9 10 
 
 
            Dimensions 
 
Covariance Parameters             2 
Columns in X                      4 
Columns in Z                     10 
Subjects                          1 
Max Obs Per Subject             111 
 
 






Number of Observations Read             111 
Number of Observations Used             111 
Number of Observations Not Used           0 
 
 
                     Iteration History 
 
Iteration    Evaluations    -2 Res Log Like       Criterion 
 
        0              1       541.57063759 
        1              3       526.39526192      0.00090419 
        2              1       526.22079006      0.00010363 
        3              1       526.20244756      0.00000184 
        4              1       526.20214234      0.00000000 
 
 
                   Convergence criteria met. 
Dependent variable = __5B950                                      13:54 
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The Mixed Procedure 
 
Covariance Parameter 
      Estimates 
 
Cov Parm     Estimate 
 
Dog            2.1145 
Residual       6.3278 
 
 
           Fit Statistics 
 
-2 Res Log Likelihood           526.2 
AIC (smaller is better)         530.2 
AICC (smaller is better)        530.3 
BIC (smaller is better)         530.8 
 
 
        Type 3 Tests of Fixed Effects 
 
              Num     Den 
Effect         DF      DF    F Value    Pr > F 
 
Position        2     101       1.30    0.2775 
 
 
                            Least Squares Means 
 
                                    Standard 
Effect      Position    Estimate       Error      DF    t Value    Pr > 
|t| 
 






Position    2            99.4852      0.8935     101     111.35      
<.0001 




                          Differences of Least Squares Means 
 
                                                Standard 
Effect      Position    Position    Estimate       Error      DF    t 
Value    Pr > |t| 
 
Position    1           2            -1.9045      1.2830     101      -
1.48      0.1408 
Position    1           3            -1.7170      1.3473     101      -
1.27      0.2055 
Position    2           3             0.1875      1.3289     101       
0.14      0.8881 
Dependent variable = __5R1000                                     13:54 
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The Mixed Procedure 
 
                  Model Information 
 
Data Set                     WORK.TEMP 
Dependent Variable           __5R1000 
Covariance Structure         Variance Components 
Estimation Method            REML 
Residual Variance Method     Profile 
Fixed Effects SE Method      Model-Based 
Degrees of Freedom Method    Containment 
 
 
              Class Level Information 
 
Class       Levels    Values 
 
Position         3    1 2 3 
Dog             10    1 2 3 4 5 6 7 8 9 10 
 
 
            Dimensions 
 
Covariance Parameters             2 
Columns in X                      4 
Columns in Z                     10 
Subjects                          1 
Max Obs Per Subject             111 
 
 
          Number of Observations 
 
Number of Observations Read             111 
Number of Observations Used             111 







                     Iteration History 
 
Iteration    Evaluations    -2 Res Log Like       Criterion 
 
        0              1       874.42208504 
        1              2       853.07143640      0.00000004 
        2              1       853.07142244      0.00000000 
 
 
                   Convergence criteria met. 
 
 
Dependent variable = __5R1000                                     13:54 
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The Mixed Procedure 
 
Covariance Parameter 
      Estimates 
 
Cov Parm     Estimate 
 
Dog           70.0212 
Residual       127.35 
 
 
           Fit Statistics 
 
-2 Res Log Likelihood           853.1 
AIC (smaller is better)         857.1 
AICC (smaller is better)        857.2 
BIC (smaller is better)         857.7 
 
 
        Type 3 Tests of Fixed Effects 
 
              Num     Den 
Effect         DF      DF    F Value    Pr > F 
 
Position        2     101       1.83    0.1655 
 
 
                            Least Squares Means 
 
                                    Standard 
Effect      Position    Estimate       Error      DF    t Value    Pr > 
|t| 
 
Position    1            17.8587      5.1205     101       3.49      
0.0007 
Position    2            30.8488      4.8304     101       6.39      
<.0001 








                          Differences of Least Squares Means 
 
                                                Standard 
Effect      Position    Position    Estimate       Error      DF    t 
Value    Pr > |t| 
 
Position    1           2           -12.9901      7.0394     101      -
1.85      0.0679 
Position    1           3            -3.6240      7.4161     101      -
0.49      0.6261 
Position    2           3             9.3661      7.2188     101       
1.30      0.1974 
 
One-way ANOVA: C5 versus C6  
 
Source   DF      SS     MS      F      P 
C6        3   716.7  238.9  18.04  0.000 
Error   316  4184.2   13.2 
Total   319  4900.9 
 
S = 3.639   R-Sq = 14.62%   R-Sq(adj) = 13.81% 
 
 
                             Individual 95% CIs For Mean Based on 
                             Pooled StDev 
Level      N    Mean  StDev  ------+---------+---------+---------+--- 
BA-B95    80   95.84   5.56  (----*----) 
DART-B95  80  100.00   0.00                             (-----*----) 
POP-B95   80   97.58   3.98             (-----*----) 
ST-B95    80   97.25   2.50           (----*-----) 
                             ------+---------+---------+---------+--- 
                                96.0      97.5      99.0     100.5 
 
Pooled StDev = 3.64 
 
 
Tukey 95% Simultaneous Confidence Intervals 
All Pairwise Comparisons among Levels of C6 
 
Individual confidence level = 98.93% 
 
 
C6 = BA-B95 subtracted from: 
 
C6         Lower  Center  Upper  -------+---------+---------+---------+-- 
DART-B95   2.683   4.160  5.637                              (-----*-----) 
POP-B95    0.259   1.736  3.213                    (-----*-----) 
ST-B95    -0.062   1.415  2.892                   (-----*-----) 
                                 -------+---------+---------+---------+-- 
                                     -2.5       0.0       2.5       5.0 
 
 
C6 = DART-B95 subtracted from: 
 
C6        Lower  Center   Upper  -------+---------+---------+---------+-- 
POP-B95  -3.901  -2.424  -0.947   (-----*-----) 
ST-B95   -4.222  -2.745  -1.268  (-----*-----) 
                                 -------+---------+---------+---------+-- 







C6 = POP-B95 subtracted from: 
 
C6       Lower  Center  Upper  -------+---------+---------+---------+-- 
ST-B95  -1.798  -0.321  1.156            (-----*-----) 
                               -------+---------+---------+---------+-- 
                                   -2.5       0.0       2.5       5.0 
 
Tukey 95.0% Simultaneous Confidence Intervals 
Response Variable C5 
All Pairwise Comparisons among Levels of C6 
C6 = BA-B95  subtracted from: 
 
C6           Lower  Center  Upper  ----+---------+---------+---------+-- 
DART-B95   2.68320   4.160  5.637                         (----*----) 
POP-B95    0.25945   1.736  3.213                 (----*----) 
ST-B95    -0.06180   1.415  2.892                (----*----) 
                                   ----+---------+---------+---------+-- 
                                    -3.0       0.0       3.0       6.0 
 
 
C6 = DART-B95  subtracted from: 
 
C6        Lower  Center   Upper  ----+---------+---------+---------+-- 
POP-B95  -3.901  -2.424  -0.947   (----*----) 
ST-B95   -4.222  -2.745  -1.268  (----*----) 
                                 ----+---------+---------+---------+-- 
                                  -3.0       0.0       3.0       6.0 
 
 
C6 = POP-B95  subtracted from: 
 
C6       Lower   Center  Upper  ----+---------+---------+---------+-- 
ST-B95  -1.798  -0.3213  1.156          (----*----) 
                                ----+---------+---------+---------+-- 
                                 -3.0       0.0       3.0       6.0 
 
 
Tukey Simultaneous Tests 
Response Variable C5 
All Pairwise Comparisons among Levels of C6 
C6 = BA-B95  subtracted from: 
 
          Difference       SE of           Adjusted 
C6          of Means  Difference  T-Value   P-Value 
DART-B95       4.160      0.5753    7.230    0.0000 
POP-B95        1.736      0.5753    3.018    0.0136 
ST-B95         1.415      0.5753    2.459    0.0664 
 
 
C6 = DART-B95  subtracted from: 
 
         Difference       SE of           Adjusted 
C6         of Means  Difference  T-Value   P-Value 
POP-B95      -2.424      0.5753   -4.213    0.0001 
ST-B95       -2.745      0.5753   -4.771    0.0000 
 
 
C6 = POP-B95  subtracted from: 
 
        Difference       SE of           Adjusted 
C6        of Means  Difference  T-Value   P-Value 







One-way ANOVA: C5 versus C6  
 
Source   DF       SS      MS      F      P 
C6        3   9102.9  3034.3  73.11  0.000 
Error   316  13114.1    41.5 
Total   319  22217.0 
 
S = 6.442   R-Sq = 40.97%   R-Sq(adj) = 40.41% 
 
 
                             Individual 95% CIs For Mean Based on 
                             Pooled StDev 
Level      N    Mean  StDev  --+---------+---------+---------+------- 
BA-R95    80   6.650  7.733              (--*--) 
DART-R95  80   0.390  0.508  (--*--) 
POP-R95   80  14.990  9.260                               (--*--) 
ST-R95    80   4.403  4.494          (--*--) 
                             --+---------+---------+---------+------- 
                             0.0       5.0      10.0      15.0 
 
Pooled StDev = 6.442 
 
 
Tukey 95% Simultaneous Confidence Intervals 
All Pairwise Comparisons among Levels of C6 
 
Individual confidence level = 98.93% 
 
 
C6 = BA-R95 subtracted from: 
 
C6         Lower  Center   Upper  -------+---------+---------+---------+-- 
DART-R95  -8.875  -6.260  -3.646          (--*-) 
POP-R95    5.726   8.340  10.954                         (-*--) 
ST-R95    -4.861  -2.246   0.368              (--*-) 
                                  -------+---------+---------+---------+-- 
                                       -10         0        10        20 
 
 
C6 = DART-R95 subtracted from: 
 
C6        Lower  Center   Upper  -------+---------+---------+---------+-- 
POP-R95  11.986  14.600  17.215                               (--*-) 
ST-R95    1.399   4.014   6.628                    (--*--) 
                                 -------+---------+---------+---------+-- 
                                      -10         0        10        20 
 
 
C6 = POP-R95 subtracted from: 
 
C6        Lower   Center   Upper  -------+---------+---------+---------+-- 
ST-R95  -13.201  -10.587  -7.972      (-*--) 
                                  -------+---------+---------+---------+-- 
                                       -10         0        10        20 
 
General Linear Model: C5 versus C6  
 
Factor  Type   Levels  Values 







Analysis of Variance for C5, using Adjusted SS for Tests 
 
Source   DF   Seq SS   Adj SS  Adj MS      F      P 
C6        3   9102.9   9102.9  3034.3  73.11  0.000 
Error   316  13114.1  13114.1    41.5 
Total   319  22217.0 
 
 
S = 6.44208   R-Sq = 40.97%   R-Sq(adj) = 40.41% 
 
 
Unusual Observations for C5 
 
Obs       C5      Fit  SE Fit  Residual  St Resid 
  4  32.4000  14.9900  0.7202   17.4100      2.72 R 
 20  45.1000  14.9900  0.7202   30.1100      4.70 R 
 29  32.4000  14.9900  0.7202   17.4100      2.72 R 
 39  45.1000  14.9900  0.7202   30.1100      4.70 R 
 44  32.4000  14.9900  0.7202   17.4100      2.72 R 
 48  45.1000  14.9900  0.7202   30.1100      4.70 R 
 63  45.1000  14.9900  0.7202   30.1100      4.70 R 
 67  32.4000  14.9900  0.7202   17.4100      2.72 R 
 84  19.5000   6.6500  0.7202   12.8500      2.01 R 
100  34.6000   6.6500  0.7202   27.9500      4.37 R 
104  19.5000   6.6500  0.7202   12.8500      2.01 R 
120  34.6000   6.6500  0.7202   27.9500      4.37 R 
124  19.5000   6.6500  0.7202   12.8500      2.01 R 
128  34.6000   6.6500  0.7202   27.9500      4.37 R 
143  34.6000   6.6500  0.7202   27.9500      4.37 R 
147  19.5000   6.6500  0.7202   12.8500      2.01 R 
180  19.7000   4.4035  0.7202   15.2965      2.39 R 
200  19.7000   4.4035  0.7202   15.2965      2.39 R 
208  19.7000   4.4035  0.7202   15.2965      2.39 R 
223  19.7000   4.4035  0.7202   15.2965      2.39 R 
 
R denotes an observation with a large standardized residual. 
 
 
Least Squares Means for C5 
 
C6           Mean  SE Mean 
BA-R95     6.6500   0.7202 
DART-R95   0.3898   0.7202 
POP-R95   14.9900   0.7202 
ST-R95     4.4035   0.7202 
 
 
Tukey 95.0% Simultaneous Confidence Intervals 
Response Variable C5 
All Pairwise Comparisons among Levels of C6 
C6 = BA-R95  subtracted from: 
 
C6         Lower  Center   Upper  ---+---------+---------+---------+--- 
DART-R95  -8.875  -6.260  -3.646      (--*-) 
POP-R95    5.726   8.340  10.954                     (-*--) 
ST-R95    -4.861  -2.246   0.368          (--*-) 
                                  ---+---------+---------+---------+--- 
                                   -10         0        10        20 
 
 
C6 = DART-R95  subtracted from: 
 





POP-R95  11.986  14.600  17.215                           (--*-) 
ST-R95    1.399   4.014   6.628                (--*--) 
                                 ---+---------+---------+---------+--- 
                                  -10         0        10        20 
 
 
C6 = POP-R95  subtracted from: 
 
C6       Lower  Center   Upper  ---+---------+---------+---------+--- 
ST-R95  -13.20  -10.59  -7.972  (-*--) 
                                ---+---------+---------+---------+--- 
                                 -10         0        10        20 
 
 
Tukey Simultaneous Tests 
Response Variable C5 
All Pairwise Comparisons among Levels of C6 
C6 = BA-R95  subtracted from: 
 
          Difference       SE of           Adjusted 
C6          of Means  Difference  T-Value   P-Value 
DART-R95      -6.260       1.019   -6.146    0.0000 
POP-R95        8.340       1.019    8.188    0.0000 
ST-R95        -2.246       1.019   -2.206    0.1217 
 
 
C6 = DART-R95  subtracted from: 
 
         Difference       SE of           Adjusted 
C6         of Means  Difference  T-Value   P-Value 
POP-R95      14.600       1.019   14.334    0.0000 
ST-R95        4.014       1.019    3.941    0.0005 
 
 
C6 = POP-R95  subtracted from: 
 
        Difference       SE of           Adjusted 
C6        of Means  Difference  T-Value   P-Value 
ST-R95      -10.59       1.019   -10.39    0.0050 
 
 
One-way ANOVA: C5 versus C6  
 
Source   DF      SS     MS      F      P 
C6        3  1150.5  383.5  22.29  0.000 
Error   316  5437.6   17.2 
Total   319  6588.1 
 
S = 4.148   R-Sq = 17.46%   R-Sq(adj) = 16.68% 
 
 
                             Individual 95% CIs For Mean Based on 
                             Pooled StDev 
Level       N   Mean  StDev  -----+---------+---------+---------+---- 
BA-R100    80  3.256  4.855                   (---*----) 
DART-R100  80  0.006  0.016  (----*----) 
POP-R100   80  5.065  6.370                            (---*----) 
ST-R100    80  1.490  2.165          (---*----) 
                             -----+---------+---------+---------+---- 
                                0.0       2.0       4.0       6.0 
 







Tukey 95% Simultaneous Confidence Intervals 
All Pairwise Comparisons among Levels of C6 
 
Individual confidence level = 98.93% 
 
 
C6 = BA-R100 subtracted from: 
 
C6          Lower  Center   Upper  ---------+---------+---------+---------+ 
DART-R100  -4.933  -3.250  -1.566       (----*----) 
POP-R100    0.125   1.809   3.493                     (----*----) 
ST-R100    -3.450  -1.766  -0.083           (----*----) 
                                   ---------+---------+---------+---------+ 
                                         -3.5       0.0       3.5       7.0 
 
 
C6 = DART-R100 subtracted from: 
 
C6         Lower  Center  Upper  ---------+---------+---------+---------+ 
POP-R100   3.375   5.059  6.742                               (---*----) 
ST-R100   -0.200   1.483  3.167                    (----*----) 
                                 ---------+---------+---------+---------+ 
                                       -3.5       0.0       3.5       7.0 
 
 
C6 = POP-R100 subtracted from: 
 
C6        Lower  Center   Upper  ---------+---------+---------+---------+ 
ST-R100  -5.259  -3.575  -1.892      (----*----) 
                                 ---------+---------+---------+---------+ 
                                       -3.5       0.0       3.5       7.0 
 
General Linear Model: C5 versus C6  
 
Factor  Type   Levels  Values 
C6      fixed       4  BA-R100, DART-R100, POP-R100, ST-R100 
 
 
Analysis of Variance for C5, using Adjusted SS for Tests 
 
Source   DF   Seq SS   Adj SS  Adj MS      F      P 
C6        3  1150.53  1150.53  383.51  22.29  0.000 
Error   316  5437.56  5437.56   17.21 
Total   319  6588.09 
 
 
S = 4.14819   R-Sq = 17.46%   R-Sq(adj) = 16.68% 
 
 
Unusual Observations for C5 
 
Obs       C5     Fit  SE Fit  Residual  St Resid 
  4  13.7000  5.0650  0.4638    8.6350      2.09 R 
 20  28.2000  5.0650  0.4638   23.1350      5.61 R 
 30  13.7000  5.0650  0.4638    8.6350      2.09 R 
 33  28.2000  5.0650  0.4638   23.1350      5.61 R 
 44  13.7000  5.0650  0.4638    8.6350      2.09 R 
 48  28.2000  5.0650  0.4638   23.1350      5.61 R 
 63  28.2000  5.0650  0.4638   23.1350      5.61 R 





100  20.7000  3.2560  0.4638   17.4440      4.23 R 
120  20.7000  3.2560  0.4638   17.4440      4.23 R 
128  20.7000  3.2560  0.4638   17.4440      4.23 R 
143  20.7000  3.2560  0.4638   17.4440      4.23 R 
 
R denotes an observation with a large standardized residual. 
 
 
Least Squares Means for C5 
 
C6            Mean  SE Mean 
BA-R100    3.25600   0.4638 
DART-R100  0.00638   0.4638 
POP-R100   5.06500   0.4638 
ST-R100    1.48950   0.4638 
 
 
Tukey 95.0% Simultaneous Confidence Intervals 
Response Variable C5 
All Pairwise Comparisons among Levels of C6 
C6 = BA-R100  subtracted from: 
 
C6          Lower  Center   Upper  -----+---------+---------+---------+- 
DART-R100  -4.933  -3.250  -1.566   (----*----) 
POP-R100    0.125   1.809   3.493                 (----*----) 
ST-R100    -3.450  -1.767  -0.083       (----*----) 
                                   -----+---------+---------+---------+- 
                                     -3.5       0.0       3.5       7.0 
 
 
C6 = DART-R100  subtracted from: 
 
C6          Lower  Center  Upper  -----+---------+---------+---------+- 
POP-R100   3.3751   5.059  6.742                           (---*----) 
ST-R100   -0.2004   1.483  3.167                (----*----) 
                                  -----+---------+---------+---------+- 
                                    -3.5       0.0       3.5       7.0 
 
 
C6 = POP-R100  subtracted from: 
 
C6        Lower  Center   Upper  -----+---------+---------+---------+- 
ST-R100  -5.259  -3.575  -1.892  (----*----) 
                                 -----+---------+---------+---------+- 
                                   -3.5       0.0       3.5       7.0 
 
 
Tukey Simultaneous Tests 
Response Variable C5 
All Pairwise Comparisons among Levels of C6 
C6 = BA-R100  subtracted from: 
 
           Difference       SE of           Adjusted 
C6           of Means  Difference  T-Value   P-Value 
DART-R100      -3.250      0.6559   -4.955    0.0000 
POP-R100        1.809      0.6559    2.758    0.0297 
ST-R100        -1.767      0.6559   -2.693    0.0356 
 
 
C6 = DART-R100  subtracted from: 
 
          Difference       SE of           Adjusted 





POP-R100       5.059      0.6559    7.713    0.0000 
ST-R100        1.483      0.6559    2.261    0.1072 
 
 
C6 = POP-R100  subtracted from: 
 
         Difference       SE of           Adjusted 
C6         of Means  Difference  T-Value   P-Value 
ST-R100      -3.575      0.6559   -5.451    0.0000 
